[
    {
        "id": "6278da4456bf9aee6f00000f",
        "question": "Potential immunomodulatory, antiinflammatory, anti-angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma. \n In 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic and immunomodulatory activities, and its therapeutic effect on myeloma. \n Thalidomide is an immunomodulatory agent; although its mechanisms of action are not fully understood, many authors have described its anti-inflammatory and immunosuppressive properties \n Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies \n After nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs (IMiDs) \n Thalidomide has antiangiogenic and immunomodulatory properties and has recently been used in the management of human malignancies. \n Thalidomide is a drug that, since its development, has made history in the world of medicine--having been withdrawn and now has returned with a boom as an anticancer and immunomodulatory drug. \n Thalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno-modulatory drug. \n Thalidomide is attracting growing interest because of its reported immunomodulatory and anti-inflammatory properties. \n Only in the last several years has thalidomide been aggressively investigated for its antiangiogenic potential and immunomodulatory properties in various tumor types. \n After nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs (IMiDs). \n In the present review an attempt is made to highlight the immunomodulatory action of thalidomide in various pathologic conditions. \n Thalidomide and its immunomodulatory analogues have numerous effects on the body's immune system, including potential anti-cancer and anti-inflammatory activities. \n Thalidomide is an immunomodulatory agent; although its mechanisms of action are not fully understood, many authors have described its anti-inflammatory and immunosuppressive properties. \n Thalidomide (Thal) has antiangiogenic and immunomodulatory activity. \n Thalidomide is an immunomodulatory drug (IMiD) with proven therapeutic action in several autoimmune/inflammatory diseases; \n The immunomodulatory agents thalidomide and lenalidomide and the proteasome inhibitor bortezomib are now routine components of MM therapy \n Although thalidomide was withdrawn in the 1960s after its teratogenic property was recognized, it was subsequently found that this drug possesses immunomodulatory and anti-inflammatory effects. \n  Its immunological effects were known already from earlier studies. Nowadays its use is accepted in myeloma therapy. \n Therapeutics that have proven to be highly effective include the immunomodulatory drug thalidomide and its newer analogs, lenalidomide and pomalidomide, as well as the proteasome inhibitors bortezomib and carfilzomib \n As immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases \n Its effectiveness in the clinic has been ascribed to wide-ranging properties, including anti-TNF-alpha, T-cell costimulatory and antiangiogenic activity. \n Thalidomide has various immunomodulatory effects. Thalidomide inhibits TNF alpha production, has T-cell costimulatory properties and modulates the expression of cell surface molecules on leukocytes in vivo. \n  thalidomide has been a target of active investigation in both malignant and inflammatory conditions. Although initially developed for its sedative properties, decades of investigation have identified a multitude of biological effects that led to its classification as an immunomodulatory drug (IMiD). \n The mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins. \n This effect is probably due to a direct influence on the immune system \n Is thalidomide used as an immunomodulatory drug nowadays?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6278d0a756bf9aee6f00000e",
        "question": "homodimerized p85\u03b1 \n p110\u03b1-free p85\u03b1 homodimerizes \n homodimeric but not monomeric p85\u03b1 \n Does p85\u03b1 homodimerize?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6276d2d956bf9aee6f000002",
        "question": "These findings suggest that the use of ACE-I and ARB is not associated with adverse outcomes and may be associated with improved outcomes in COVID-19, which is immediately relevant to care of the many patients on these medications. \n There are theoretical concerns that angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) could increase the risk of severe Covid-19. \n ACEIs and ARBs were associated with a slight reduction in Covid-19 hospitalization risk compared with treatment with other first-line antihypertensives (OR for ACEIs 0.95, 95% CI 0.92-0.98; OR for ARBs 0.94, 95% CI 0.90-0.97). \n There were no meaningful differences in risk for ACEIs compared with ARBs. \n ACEIs and ARBs were not associated with an increased risk of Covid-19 hospitalization or with hospitalization involving ICU admission, invasive mechanical ventilation, or death. \n In patients with HTN and COVID-19, neither ACEi nor ARBs were independently associated with mortality. \n Our data confirm Specialty Societal recommendations, suggesting that treatment with ACEIs or ARBs should not be discontinued because of COVID-19. \n Random-effects meta-analysis showed ACEI/ARB treatment was significantly associated with a lower risk of mortality in hypertensive COVID-19 patients (odds ratio [OR]\u2009=\u20090.624, 95% confidence interval [CI]\u2009=\u20090.457-0.852, p\u2009=\u2009.003, I2 \u2009=\u200974.3%). \n In addition, the ACEI/ARB treatment was associated with a lower risk of ventilatory support (OR\u2009=\u20090.682, 95% CI\u2009=\u20090.475-1.978, p\u2009=\u2009.037, I2 \u2009=\u20090.0%). In conclusion, these results suggest that ACEI/ARB medications should not be discontinued for hypertensive patients in the context of COVID-19 pandemic. \n Use of ACE-I or ARB medications was not associated with increased risk of hospitalization, intensive care unit admission, or death. Compared to patients with charted past medical history, there was a lower risk of hospitalization for patients on ACE-I (odds ratio (OR) 0.43; 95% confidence interval (CI) 0.19-0.97; P = 0.0426) and ARB (OR 0.39; 95% CI 0.17-0.90; P = 0.0270). \n The second analysis showed that the use of ACEI and/or ARB did not affect in-hospital mortality (risk ratio [RR] 95% [CI]]\u2009=\u20090.88 [0.64-1.20], p\u2009=\u20090.42). The subgroup analysis by limiting studies of patients with hypertension showed ACEI and/or ARB use was associated with a significant reduction of in-hospital mortality compared with no ACEI or ARB use (RR [CI]\u2009=\u20090.66 [0.49-0.89], p\u2009=\u20090.004). Our analysis demonstrated that ACEI and/or ARB use was associated neither with testing positive rates of COVID-19 nor with mortality of COVID-19 patients. \n ACEIs/ARBs are protective factors against mortality in COVID-19 patients with HTN, and these agents can be considered potential therapeutic options in this disease. \n There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes. \n Although further research on the influence of blood-pressure-lowering drugs, including those not targeting the renin-angiotensin system, is warranted, there are presently no compelling clinical data showing that ACEIs and ARBs increase the likelihood of contracting COVID-19 or worsen the outcome of SARS-CoV\u20112 infections \n There has been a lot of speculation that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) may be at increased risk for adverse outcomes \n ACEIs and ARBs do not promote a more severe outcome of COVID-19. \n Meta-analysis showed no significant increase in the risk of COVID-19 infection (odds ratio [OR]: 0.95, 95%CI: 0.89-1.05) in patients receiving ACEI/ARB therapy, and ACEI/ARB therapy was associated with a decreased risk of severe COVID-19 (OR: 0.75, 95%CI: 0.59-0.96) and mortality (OR: 0.52, 95%CI: 0.35-0.79). \n Subgroup analyses showed among the general population, ACEI/ARB therapy was associated with reduced severe COVID-19 infection (OR: 0.79, 95%CI: 0.60-1.05) and all-cause mortality (OR: 0.31, 95%CI: 0.13-0.75), and COVID-19 infection (OR: 0.85, 95% CI: 0.66-1.08) were not increased. \n On the basis of the available evidence, ACEI/ARB therapy should be continued in patients who are at risk for, or have COVID-19, either in general population or hypertension patients. \n Some studies of hospitalized patients suggested that the risk of death and/or severe illness due to COVID-19 is not associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor type 1 blockers (ARBs) \n Available evidence, in particular, data from human studies, does not support the hypothesis that ACEI/ARB use increases ACE2 expression and the risk of complications from COVID-19. We conclude that patients being treated with ACEIs and ARBs should continue their use for approved indications. \n Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6278ddfe56bf9aee6f000013",
        "question": "North Star Ambulatory Assessment is practical and reliable. \n allow assessment of high-functioning boys with Duchenne muscular dystrophy. \n agnosis and tracking of symptom progression of DMD usually relies on creatine kinase tests, evaluation of patient performance in various ambulatory assessments, and detection of dystrophin from muscle biopsies, which are invasive and painful for the patient. While the \n Aim: Using baseline data from a clinical trial of domagrozumab in Duchenne muscular dystrophy, we evaluated the correlation between functional measures and quantitative MRI assessments of thigh muscle. Patients & methods: Analysis included timed functional tests, knee extension/strength and North St \n A New Functional Scale and Ambulatory Functional Classification of Duchenne Muscular Dystrophy: Scale Development and Preliminary Analyses of Reliability and Validity. \n his preliminary investigation describes the relationship between community ambulation measured by the StepWatch activity monitor and the current standard of functional assessment, the 6-minute walk test, in ambulatory boys with Duchenne muscular dystrophy (n = 16) and healthy controls (n = 13). All \n ith strength assessments. MV index, fat fraction and T2-mapping measures had moderate correlations (r \u223c\u00a00.5) to all functional tests, North Star Ambulatory Assessment and age. Conclusion: The moderate correlation between functional tests, age and baseline MRI measures supports MRI as a biomarker in Duchenn \n on with clinically meaningful outcome measures such as North Star Ambulatory Assessment (NSAA) and 6\u2009minute walk test (6MWT) is paramount for biomarker qualification. In this stu \n Quantitative muscle strength assessment in duchenne muscular dystrophy: longitudinal study and correlation with functional measures. \n The 6-minute walk test, timed 10-meter walk/run test, and supine-up time are commonly used timed functional tests that also sufficiently monitor changes in muscle function; however, they strongly depend on patient collaboration \n Conclusion: The moderate correlation between functional tests, age and baseline MRI measures supports MRI as a biomarker in Duchenne muscular dystrophy clinical trials. \n Currently, functional measures continue to serve as the primary outcome for the majority of DMD clinical trials. \n Patients & methods: Analysis included timed functional tests, knee extension/strength and North Star\u00a0Ambulatory Assessment. \n The 6-minute walk test, timed 10-meter walk/run test, and supine-up time are commonly used timed functional tests that also sufficiently monitor changes in muscle function; however, they strongly depend on patient collaboration. \n We have developed a new scale and the associated classification system, to assess the functional ability of children diagnosed with DMD. Preliminary evaluation of the psychometric properties of the functional scale and classification systems indicate sufficient reliability and concurrent validity. \n Quantitative MRI is an objective and sensitive biomarker to detect subclinical changes, though the examination costs may be a reason for its limited use. In this study, a high correlation between all clinical assessments and quantitative MRI scans was found. The combinational use of these methods provides a better understanding about disease progression; however, longitudinal studies are needed to validate their reliability. \n The children's functional performance was assessed using 6-minute walk tests and timed performance tests. The correlations between the flexibilities of the lower limb muscles and the performance tests were examined. \n The flexibilities of the lower extremity muscles were found to be correlated to the 6-minute walk tests and the timed performance tests. The flexibility of the hamstrings (r\u2009=\u2009-.825), the gastrocnemius muscles (r\u2009=\u2009.545), the hip flexors (r\u2009=\u2009.481), and the tensor fascia latae (r\u2009=\u2009.445) were found to be correlated with functional performance as measured by the 6-minute walk tests (P\u2009<\u2009.05) \n Nine biomarkers have been identified that correlate with disease milestones, functional tests and respiratory capacity. Together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring. \n  In conclusion, the motor function measure and timed function tests measure disease severity in a highly comparable fashion and all tests correlated with quantitative muscle MRI values quantifying fatty muscle degeneration. \n  This study is to date the most thorough long-term evaluation of QMT in a cohort of DMD patients correlated with other measures, such as the North Star Ambulatory Assessment (NSAA) or three 6-min walk test (6MWT). \n The MFM scale was a useful instrument in the follow up of patients with DMD. Moreover, it is a more comprehensive scale to assess patients and very good for conducting trials to evaluate treatment. \n MD subjects were evaluated using the Vignos lower extremity functional rating, and tests including 6\u00a0min walk test (6MWT) and 10\u00a0m walk. \n TFTs appear to be slightly more responsive and predictive of disease progression than the 6MWT in 7-12.9 year olds. \n herefore, in our group of ambulant patients with DMD, timed functional testing was the most sensitive parameter to determine the extent of disease progression. Timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with DMD and possibly in other neuromuscular disorders. \n Time to rise is a useful and simple tool in the screening of neuromuscular disorders such as Duchenne muscular dystrophy, \n he muscle strength of the wrist extensors and the radial deviation range of motion at the wrist were found to be strongly correlated with six of the seven tasks assessed. These two clinical assessments appear to be good indicators of overall wrist and hand function. \n Are functional tests a good biomarker for Duchenne Muscular Dystrophy?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "627926bc56bf9aee6f00001a",
        "question": "Findings indicate that clinical symptoms alone would be insufficient to distinguish between coronavirus disease 2019 and other respiratory infections (eg, influenza) and/or to evaluate the effects of preventive interventions (eg, vaccinations). \n Our reasoning highlights how challenging a balanced approach to a patient with fever and flu-like symptoms can be. At present, clinical workup of COVID-19 remains a hard task to accomplish. \n In our retrospective cohort study comparing the clinical presentation of COVID-19 and other respiratory viral infections, we found that anosmia and dysgeusia were symptoms independently associated with COVID-19 and can be important differentiating symptoms in patients presenting with acute respiratory illness. On the other hand, laboratory abnormalities and radiological findings were not statistically different between the two groups. \n COVID-19 has a similar pattern of infection, clinical symptoms, and chest imaging findings to influenza pneumonia. \n Here, we hypothesize the order of symptom occurrence could help patients and medical professionals more quickly distinguish COVID-19 from other respiratory diseases, yet such essential information is largely unavailable \n It is difficult to distinguish coronavirus disease-2019 (COVID-19) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings. \n Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "627a6ef856bf9aee6f000020",
        "question": "As an emergency diagnostic procedure, spinal puncture is indicated when CNS infection is suspected or to establish the diagnosis of subarachnoid hemorrhage when results of cranial computed tomography are normal. The major contraindication is elevated intracranial pressure with evidence of a mass lesion. \n Brain shift is a contraindication to LP, whether CSF pressure is raised or not, and whether papilloedema is present or not. Subsequently, recommendations are offered for indications to perform CT before LP, grouped according to the safety and clinical utility of LP. \n Death following lumbar puncture (LP) is feared by physicians. Many opinions are found in literature on the question whether computed cranial tomography (CT) should be performed before LP, to prevent herniation. \n Headache, caused by cerebrospinal fluid (CSF) hypotension, is a frequent complication of lumbar puncture; hematic patch is a therapeutic option for severe cases. The most serious complication is cerebral herniation and, for its prevention, computed tomography (CT) or cerebral magnetic resonance imaging (MRI) must always be performed before lumbar puncture: a lesion with evident mass effect is a contraindication. \n Lumbar puncture (LP) is usually contra-indicated in situations where the ICP is suspected to be high. \n Low-dose cranial computed tomography (LD-CCT) based on iterative reconstruction has been shown to have sufficient image quality to assess cerebrospinal fluid spaces (CSF) and midline structures but not to exclude subtle parenchymal pathologies. Patients without focal neurological deficits often undergo CCT before lumbar puncture (LP) to exclude contraindications to LP including brain herniation or increased CSF pressure. \n Lumbar puncture is performed routinely for diagnostic and therapeutic purposes in idiopathic intracranial hypertension, despite lumbar puncture being classically contraindicated in the setting of raised intracranial pressure. \n Although generally considered innocuous, there may be considerable danger when lumbar puncture is performed in the presence of increased intracranial pressure, especially when a mass lesion is present. \n Lumbar puncture should be avoided if focal neurologic findings suggest concomitant mass lesion, as in brain abscess, and lumbar puncture should be approached with great caution if meningitis is accompanied by evidence of significant intracranial hypertension. \n There are few abnormal CT scans presenting a contraindication for lumbar puncture and the majority of these patients usually have clinical signs to suggest raised intracranial pressure. \n Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "621ea5a53a8413c653000055",
        "question": "Biologically active epoxyeicosatrienoic acid (EET) regioisomers are synthesized from arachidonic acid by cytochrome P450 epoxygenases of endothelial, myocardial, and renal tubular cells. \n epoxyeicosatrienoic acids (EETs), synthesized by cytochrome P450 epoxygenases from arachidonic acid.  \n Epoxyeicosatrienoic acids (EETs), synthesized from arachidonic acid by cytochrome P450 epoxygenases \n Epoxyeicosatrienoic acids (EETs), which are synthesized from arachidonic acid by cytochrome P450 epoxygenases, function primarily as autocrine and paracrine effectors in the cardiovascular system and kidney.  \n Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid by cytochrome P450 epoxygenases in endothelial cells. I \n Epoxyeicosatrienoic acids (EETs), the eicosanoid biomediators synthesized from arachidonic acid by cytochrome P450 epoxygenases, \n Epoxyeicosatrienoic acids (EETs) are bioactive eicosanoids produced from arachidonic acid by cytochrome P450 epoxygenases. \n Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome (CYP) P450 epoxygenases, and to \u03c9-terminal hydroxyeicosatetraenoic acids (HETEs) by \u03c9-hydroxylases. \n Epoxyeicosatrienoic acids (EETs), synthesized from arachidonic acid by cytochrome P450 epoxygenases, are converted to dihydroxyeicosatrienoic acids by soluble epoxide hydrolase. \n Epoxyeicosatrienoic acids (EETs), which are synthesized from arachidonic acid by cytochrome P450 epoxygenases, function primarily as autocrine and paracrine effectors in the cardiovascular system and kidney. \n Epoxygenases metabolize arachidonic acid to four regioisomeric epoxyeicosatrienoic acids (EETs) and selected monohydroxyeicosatetraenoic acids (HETEs). \n Epoxyeicosatrienoic acids (EETs) are potent lipid mediators formed by cytochrome P450 epoxygenases from arachidonic acid.  \n Epoxyeicosatrienoic acids (EETs) are bioactive eicosanoids produced from arachidonic acid by cytochrome P450 epoxygenases.  \n Epoxyeicosatrienoic acids (EETs), derived from arachidonic acid by cytochrome P450 epoxygenases, are potent vasodilators that function as endothelium-derived hyperpolarizing factors in some vascular beds. E \n Epoxyeicosatrienoic acids (EETs), which are synthesized from arachidonic acid by cytochrome P450 epoxygenases, function primarily as autocrine and paracrine effectors in the cardiovascular system and kidney. T \n poxyeicosatrienoic acids (EETs) are epoxy lipids derived from metabolism of arachidonic acid by cytochrome P450 epoxygenases. W \n he vascular endothelium metabolizes arachidonic acid by cytochrome P450 epoxygenases to epoxyeicosatrienoic acids or EETs. \n Epoxyeicosatrienoic acids (EETs) are the epoxidation products of arachidonic acid catalyzed by cytochrome P450 (CYP) epoxygenases, which possess multiple biological activities. In  \n OBJECTIVE: Arachidonic acid metabolism by cytochrome P450 (CYP) epoxygenases leads to epoxyeicosatrienoic acids (EETs), which are eicosanoids with vasodilator and anti-inflammatory pro \n Cytochrome P450 (CYP) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids (EETs), which play important and diverse roles in the cardiovascular system. Th \n Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites produced by cytochrome P450 epoxygenases which are highly expressed in hepatocytes.  \n Epoxyeicosatrienoic acids (EETs) are epoxides of arachidonic acid generated by cytochrome P450 (CYP) epoxygenases. \n Although eicosanoids, including prostaglandins and leukotrienes, are best known as products of arachidonic acid metabolism by cyclooxygenases and lipoxygenases, arachidonic acid is also a substrate for another enzymatic pathway, the cytochrome P450 (CYP) system. \n Epoxyeicosatrienoic acids (EETs), lipid mediators synthesized from arachidonic acid by cytochrome P-450 epoxygenases, are converted by soluble epoxide hydrolase (SEH) to the corresponding dihydroxyeicosatrienoic acids (DHETs). \n Epoxyeicosatrienoic acids (EETs) are synthesized from arachidonic acid by cytochrome P450 epoxygenases in endothelial cells. \n Epoxyeicosatrienoic acids (EETs), the eicosanoid biomediators synthesized from arachidonic acid by cytochrome P450 epoxygenases, are inactivated in many tissues by conversion to dihydroxyeicosatrienoic acids (DHETs). \n Epoxyeicosatrienoic acids (EETs) are potent lipid mediators formed by cytochrome P450 epoxygenases from arachidonic acid. \n Recent studies show that mouse epidermis expresses CYP2B19, a keratinocyte-specific epoxygenase that generates 11,12- and 14,15-epoxyeicosatrienoic (EET) acids from arachidonate. \n Identification of rabbit cytochromes P450 2C1 and 2C2 as arachidonic acid epoxygenases. \n Epoxyeicosatrienoic acids (EETs) are formed from arachidonic acid by the action of P450 epoxygenases (CYP2C and CYP2J). \n Epoxyeicosatrienoic acids (EETs) are generated from arachidonic acid by cytochrome P450 (CYP) epoxygenases. \n Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6027446d1cb411341a0000dd",
        "question": "After a median follow-up of 47\u00b75 months (IQR 42\u00b73-53\u00b73), incidence of primary endpoint events was not significantly different between the trimetazidine group (700 [23\u00b73%] patients) and the placebo group (714 [23\u00b77%]; hazard ratio 0\u00b798 [95% CI 0\u00b788-1\u00b709], p=0\u00b773). When analysed individually, there were no significant differences in the incidence of the components of the primary endpoint between the treatment groups.  \n INTERPRETATION: Our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful PCI, does not influence the recurrence of angina or the outcome; these findings should be taken into account when considering the place of trimetazidine in clinical practice.  \n Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62211d6f3a8413c65300006f",
        "question": "Currently, an increasing body of evidence has demonstrated that 1) majority of circRNAs are evolutionarily conserved across species, stable, and resistant to RNase R degradation,  \n Circular RNA (circRNA) has a closed-loop structure, and its 3' and 5' ends are directly covalently connected by reverse splicing, which is more stable than linear RNA. \n CircRNAs are a kind of closed circular RNA molecule widely existing in transcriptomes. Due to lack of free ends, they are not easily cleaved by RNase R, thus avoiding degradation.  \n Circular RNAs (circRNAs) are a class of newly-identified non-coding RNA that lack 5' (cap) and 3' (polyadenylation) ends and are linked by a covalent bond to form a closed loop structure. In comparison to linear RNAs, circRNAs are more resistant to exonuclease RNase R-mediated degradation with a much stronger stability due to the absence of 3' terminals \n Circular RNAs (circRNAs) own unique capabilities to communicate with nucleic acids and ribonucleoproteins and are emerging as indispensable compositions of the regulatory messages encoded in the genome. Due to lack of 3' termini, circRNAs are more resistant to degradation by exonuclease RNase R and possess greater stability than linear RNAs.  \n RNase R is a strong 3' to 5' exoribonuclease, which efficiently degrades linear RNAs, such as mRNAs and rRNAs; therefore, the circular parts of lariat RNAs and the circRNAs can be segregated from eukaryotic total RNAs by their RNase R resistance. \n Lariat RNAs and circRNAs are both RNase R resistant RNAs. \n In comparison to linear RNAs, circRNAs are more resistant to exonuclease RNase R-mediated degradation with a much stronger stability due to the absence of 3' terminals. \n Due to lack of 3' termini, circRNAs are more resistant to degradation by exonuclease RNase R and possess greater stability than linear RNAs. \n Because circRNAs are not easily degraded by exonuclease RNase R, they can exist more stably in body fluids than linear RNAs. \n Therefore, it is essential to perform the RT-qPCR validation step only after linear RNAs have been degraded using an exonuclease such as ribonuclease R (RNase R). \n is a strong 3' to 5' exoribonuclease, which efficiently degrades linear RNAs, such as mRNAs and rRNAs; therefore, the circular parts of lariat RNAs and the circRNAs can be segregated from eukaryotic total RNAs by their RNase R resistance. Thus, RNase \n sion of circRNAs is prevalent in tissues and body fluids,and their abnormal expression is related to tumor progression.circRNAs are stable even under the treatment of RNase R because of their circular conformation.As circRNAs \n e to lack of 3' termini, circRNAs are more resistant to degradation by exonuclease RNase R and possess greater stability than linear RNAs. Mo \n e circRNAs are not easily degraded by exonuclease RNase R, they can exist more stably in body fluids than linear RNAs. Based \n  is stable, difficult to cleave and resistant to RNA exonuclease or RNase R degradation. circRN \n the unique structures, circRNAs are resistant to exonuclease RNase R and maintain stability more easily than linear RNAs. Rece \n rison to linear RNAs, circRNAs are more resistant to exonuclease RNase R-mediated degradation with a much stronger stability due to the absence of 3' terminals. Conseque \n  RT-PCR analysis showed that sheep circRNAs are resistant to RNase R digestion and are expressed in prenatal and postnatal pituitary glands. GO and  \n Currently, an increasing body of evidence has demonstrated that 1) majority of circRNAs are evolutionarily conserved across species, stable, and resistant to RNase R degradation, and often exhibit cell-specific, and tissue-specific/developmental-stage-specific expression and can be largely independent of the expression levels of the linear host gene-encoded linear RNAs; 2) the biogenesis of circRNAs via back-splicing is different from the canonical splicing of linear RNAs; 3) circRNA biogenesis is regulated by specific cis-acting elements and trans-acting factors; 4) circRNAs regulate biological and pathological processes by sponging miRNAs, binding to RNA-binding protein (RBP), regulators of splicing and transcription, modifiers of parental gene expression, and regulators of protein translation or being translated into peptides in various diseases; 5) circRNAs have been identified for their enrichment and stability in exosomes and detected in body fluids such as human blood, saliva, and cerebrospinal fluids, suggesting that these exo-circRNAs have potential applications as disease biomarkers and novel therapeutic targets; 6) several circRNAs are regulated by oxidative stress and mediate reactive oxygen species (ROS) production as well as promote ROS-induced cellular death, cell apoptosis, and inflammation; 7) circRNAs have also emerged as important regulators in atherosclerotic cardiovascular disease, metabolic disease, and cancers; 8) the potential mechanisms of several circRNAs have been described in diseases, hinting at their potential applications as novel therapeutic targets. \n To prove their circularity as well as biochemically enrich these transcripts, it has become standard in the field to use the 3'-5' exonuclease RNase R. Here, we demonstrate that standard protocols involving RNase R can fail to digest >20% of all highly expressed linear RNAs, but these shortcomings can largely be overcome. \n We propose that such an R-loop dependent ciRNA degradation likely represents a mechanism that on one hand limits ciRNA accumulation by recruiting RNase H1 and on the other hand resolves R-loops for transcriptional elongation at some GC-rich ciRNA-producing loci. \n As circular RNAs (circRNAs) are resistant to degradation by exonucleases, their abundance relative to linear RNAs can be used as a surrogate marker for mRNA stability in the absence of transcription. \n The synthetic circular sponge was resistant to digestion with RNase R. Luciferase assays and functional experiments showed that the circular multi-miR sponge was more stable than its linear counterpart. \n RNAs with highly structured 3' ends, including snRNAs and histone mRNAs, are naturally resistant to RNase R, but can be efficiently degraded once a poly(A) tail has been added to their ends. \n Thousands of eukaryotic protein-coding genes generate circular RNAs that have covalently linked ends and are resistant to degradation by exonucleases. \n Are circRNAs susceptible to degradation by RNase R?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62057f1ec9dfcb9c0900002e",
        "question": "Atemoya juice significantly inhibited CYP1A2 activity in human liver microsomes, but not the activities of CYP2C9 and CYP3A. \n Does atemoya juice inhibit tye CYP3A4 enzyme?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6217db763a8413c653000028",
        "question": "Mycobacterium abscessus is unique in terms of its high morbidity and treatment failure rates \n Mycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug resistance.  \n Mycobacterium abscessus lung disease is difficult to treat due to intrinsic drug resistance and the persistence of drug-tolerant bacteria. \n Mycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non-tuberculous mycobacteria (NTM) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost.  \n Is Mycobacterium abscessus a human pathogen?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62121c583a8413c653000016",
        "question": "We here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by BCMA pyrrolobenzodiazepine (PBD) antibody drug conjugate (ADC) MEDI2228 which can augment efficacy of these immunotherapies. \n Is MEDI2228 a bispecific antibody?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "601c4ff61cb411341a000022",
        "question": " The majority of children had adjuvant therapy comprising proton beam therapy (18/59; 30.5%) or conventional radiotherapy (16/59; 27.1%). \n Proton Therapy for Craniopharyngioma - An Early Report from a Single European Centre. \n AIMS: Proton beam therapy (PBT) is being increasingly used for craniopharyngioma.  \n MATERIALS AND METHODS: Between August 2013 and July 2016, 18 patients with craniopharyngiomas were treated with 54\u00a0Cobalt Gray Equivalent (CGE) in 30 fractions over 6 weeks at our centre. \n CONCLUSIONS: Our early results are encouraging and comparable with the limited literature on PBT for craniopharyngioma. \n All of the other patients underwent proton-beam radiotherapy with no documented tumor growth (median follow-up: 20 months; range 5.1-29.9\u00a0months). \n Where aggressive subtotal resection is achieved, patients should be closely followed, with radiation initiated at the time of progression or recurrence-ideally via proton beam therapy, although three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and stereotactic radiosurgery are very appropriate in a range of circumstances, governed by access, patient age, disease architecture, and character of the recurrence. \n  This study examined parental distress in a sample of families of patients with Cp treated with proton beam therapy to identify factors for targeting psychological intervention.PROCEDURE: Prior to (n\u00a0=\u00a096) and 1 year after (n\u00a0=\u00a073) proton therapy, parents of children diagnosed with Cp (9.81\u00a0\u00b1\u00a04.42 years at baseline; 49% male) completed a self-report measure of distress, the Brief Symptom Inventory (BSI). \n Diagnoses included medulloblastoma, craniopharyngioma, ependymoma, glial tumors, germ cell tumors, and others. \n Initial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment.  \n Monte Carlo simulations were used to assess secondary neutron doses received by patients treated with proton therapy for ocular melanoma and craniopharyngioma. \n Secondary neutron doses in proton therapy treatments of ocular melanoma and craniopharyngioma. \n AIMS: Proton beam therapy (PBT) is being increasingly used for craniopharyngioma. \n LTS: Published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull-base sarcomas, and unresectable meningiomas.CONC \n In recent years, proton therapy (PT), with its physical properties of heavy ion beam, that is, Prague peak phenomenon, has been more frequently used in patients with craniopharyngioma. \n Proton beam therapy versus conformal photon radiation therapy for childhood craniopharyngioma: multi-institutional analysis of outcomes, cyst dynamics, and toxicity. \n PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxicity. \n Proton therapy for craniopharyngioma in adults: a protocol for systematic review and meta-analysis. \n We hereby report a case of a 7-year-old boy with a craniopharyngioma which had been subtotally resected and was subsequently treated with modern pencil beam proton therapy under high-precision image guidance. \n Pencil beam scanning proton therapy for the treatment of craniopharyngioma complicated with radiation-induced cerebral vasculopathies: A dosimetric and linear energy transfer (LET) evaluation. \n tial experience with proton beam therapy in childhood-onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment. R \n PURPOSE: We compared proton beam therapy (PBT) with intensity modulated radiation therapy (IMRT) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxic \n BACKGROUND AND PURPOSE: This study analyses the dosimetric and dose averaged Linear Energy transfer (LETd) correlation in paediatric craniopharyngioma (CP) patients with and without radiation-induced cerebral vasculopathies (RICVs) treated with pencil beam scanning (PBS) pro \n OBJECTIVE: The authors compared survival and multiple comorbidities in children diagnosed with craniopharyngioma who underwent gross-total resection (GTR) versus subtotal resection (STR) with radiation therapy (RT), either intensity-modulated radiation therapy (IMRT) or proton beam therapy (P \n Proton Therapy for Craniopharyngioma - An Early Report from a Single European Centre \n s. Some studies have shown that PT has advantages in the treatment of craniopharyngioma in adu \n Postoperative cerebral glucose metabolism in pediatric patients receiving proton therapy for craniopharyngioma \n Clinical equipoise: Protons and the child with craniopharyngioma. \n skull base. More public attention has been given to proton beam therapy due to the increasing number of centers now in operation or in the planning stages for offering this treatment option.METHODS: We reviewed the physical properties of protons and the clinical studies performed to justify their use in the management of skull-base tumors and determine the benefits of proton beam therapy.RESULTS: Published reports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull-base sarcomas, and unresectable meningiomas.CONCLUSIONS: Use of proton beam th \n PURPOSE: We report the results of the early cohort of patients treated for craniopharyngioma with combined proton-photon irradiation at the Massachusetts General Hospital and the Harvard Cyclotron Laboratory.METHODS AND MATERIALS: Between 1981 and 1988, 15 patients with craniopharyngioma were treated in part or entirely with fractiona \n UNLABELLED: This retrospective preliminary review evaluated the efficacy and toxicity of fractionated proton radiotherapy in the management of pediatric craniopharyngioma.METHODS: Sixteen patients, aged 7-34 years, were treated with p \n population. We evaluated the outcomes of all adult craniopharyngioma patients treated at our institution using proton therapy to report outcomes for disease control, treatment-related toxicity, and tumor response.METHODS: We analyzed 14 adult patie \n Proton radiation has been used safely and effectively for medulloblastoma, primitive neuro-ectodermal tumors, craniopharyngioma, ependymoma, germ cell intracranial tumors, low-grade glioma, retinoblastoma, rhabdomyosarcoma and other soft tissue sarcomas, Ewing's sarcoma and other bone sarcomas. \n ontroversial. The purpose of this study was to evaluate the efficacy and safety of PT for craniopharyngioma in adults.METHODS AND ANALYSIS: We will search six databases (MEDLINE, EMBASE, Web of Science, the Cochrane Library, Amed, Scopus), clinical research registration websites and grey literature, aiming to identify randomised controlled trials (RCTs) on PT for craniopharyngioma in adults between 1 \n Is proton beam therapy used for treatment of craniopharyngioma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "601d73261cb411341a00003a",
        "question": "Apert syndrome - acrocephalosyndactyly - is a rare autosomal dominant disorder representing 1:65 000 cases of living newborns. Characteristic malformations of the Apert syndrome are early craniostenosis, microviscerocranium and II-V finger syndactyly of hand and toes with proximal phalanx of the bilateral thumb \"in delta\". \n A 3-year-old child with tertiary trisomy (14 (+14q--), daughter of a mother with a balanced reciprocal translocation [46,XX,t(14;16)(q11;q24) is presented. Craniostenosis and developmental retardation were the primary presenting features in this patient. \n Saethre-Chotzen syndrome is an autosomal dominant disease characterized by craniosynostosis, ptosis, and limb and external ear abnormalities \n . For 98 patients (15%) a syndrome is associated. Third part of them has Apert syndrome, an other third part has Crouzon syndrome, and for the last third more exceptional acrocephalosyndactyly syndrome (Saethre-Chotzen, Pfeiffer) or others atypical associations, sometimes not yet described, but with an autosomal dominant inheritance. \n Coronal craniostenosis seems to be a dominant autosomal character, when scaphocephaly is more often sporadic; for both, an autosomal dominant inheritance is not excluded for some pedigrees. \n  genetic origins are not completely clear although mutations in the genes that code for fibroblast growth factor receptors have been described; depending upon the gene involved, the type of mutation and the embryological period in which the mutation itself occurs, a type of craniosynostosis arises that may involve one or more cranial sutures. The \n Saethre-Chotzen syndrome is an autosomal dominant disease characterized by craniosynostosis, ptosis, and limb and external ear abnormalities.  \n Identification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis. \n To identify and analyze causative genetic variants in nine unrelated probands mainly manifested as syndromic craniosynostosis, we reviewed the relevant medical information of the patients and performed the whole exome sequencing, further verified with Sanger sequencing and parental background. \n [Genetic counseling in craniostenosis. Results of a prospective study performed with a group of studies on craniofacial malformations]. \n Constitutional 11q interstitial deletion syndrome presents with congenital anomalies including microcephaly with craniostenosis, minor dysmorphic features, vitreoretinopathy, and renal anomalies. \n A suckling baby with microcephaly, craniostenosis, downward slanting palpebral fissues, malformed ears, cerebral, cardiac and intestinal malformation, and partial 6q25 leads to 6qter trisomy is presented. \n Its genetic origins are not completely clear although mutations in the genes that code for fibroblast growth factor receptors have been described; depending upon the gene involved, the type of mutation and the embryological period in which the mutation itself occurs, a type of craniosynostosis arises that may involve one or more cranial sutures. \n through which skull growth abnormalities are seen. It is becoming clearer that in most patients with craniosynostosis, there is regional imbalance of skull growth, which co-exists with a variety of other equally important factors, such as genetic defects, raised intracranial pressure, venous hypertension, and other brain parenchymal a \n Recent genetic studies have identified several novel genes and pathways that cause nonsyndromic craniosynostosis, providing genetic evidence linking the causes of syndromic and nonsyndromic craniosynostoses, and allowing for genotype-based prediction of risk of recurrence in some nonsyndromic families. \n Is there a genetic cause of craniostenosis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620586a8c9dfcb9c09000032",
        "question": "Moreover, pharmacokinetic studies showed that bergapten has higher absolute bioavailability and can cross the blood-brain barrier and has a great potential for treating brain disease, but the mechanism needs further clarification to make greater use of its ability to treat brain diseases.  \n Can bergapten cross the blood-brain barrier?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620be4fd3a8413c653000002",
        "question": "TIMELESS-TIPIN and UBXN-3 promote replisome disassembly during DNA replication termination in Caenorhabditis elegans. \n We show that UBXN-3 is important in\u00a0vivo for replisome disassembly in the absence of TIMELESS-TIPIN. Correspondingly, co-depletion of UBXN-3 and TIMELESS causes profound synthetic lethality. Since the human orthologue of UBXN-3, FAF1, is a candidate tumour suppressor, these findings suggest that manipulation of CMG disassembly might be applicable to future strategies for treating human cancer. \n Does TIMELESS-TIPIN participate in replisome disassembly?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "60570fe494d57fd879000026",
        "question": "the \u03b1137-141 peptide, a natural antimicrobial peptide, can be obtained after hydrolysis of hemoglobin, the main constituent of blood red part \n Beyond its physiological activity, hemoglobins are able to inhibit the growth of several microorganisms. \n A novel AMP, T. granosa hemoglobin-derived peptide (TGH1), was identified and its antimicrobial effect \n Is hemoglobin antimicrobial?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620588f9c9dfcb9c09000033",
        "question": "Furthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned. \n The phototoxicity of bergapten as a side effect should be further avoided.  \n Can bergapten cause phototoxicity?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217d9bf3a8413c653000024",
        "question": "IFNG inducible IDO/GTPCH inflammation cascade \n IFNG-induced up-regulation of indoleamine 2,3-dioxygenase (IDO) \n IFN-\u03b3-induced indoleamine-2,3-dioxgenase (IDO)  \n strong and positive correlation between IDO1 and IFNG mRNA expression levels  \n  The tryptophan-degrading activity of IDO1 was not induced significantly by Chlamydia infection alone, but the addition of IFNG greatly increased its activity.  \n Can IFNg induce the expression of IDO?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "602c2ade1cb411341a000124",
        "question": "Integrating therapeutic strategies to target TAMs to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients. \n Are TAMs good anticancer therapeutic targets?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6027434c1cb411341a0000dc",
        "question": "There were no significant between-group differences in both worst and average numerical rating scale (NRS) pain scores at 13-16 weeks after randomisation. The mean worst NRS pain score was 7\u00b71 (standard deviation [SD] 2\u00b76) in the gabapentin group and 7\u00b74 (SD 2\u00b72) in the placebo group. Mean change from baseline was -1\u00b74 (SD 2\u00b73) in the gabapentin group and -1\u00b72 (SD 2\u00b71) in the placebo group (adjusted mean difference -0\u00b720 [97\u00b75% CI -0\u00b781 to 0\u00b742]; p=0\u00b747). The mean average NRS pain score was 4\u00b73 (SD 2\u00b73) in the gabapentin group and 4\u00b75 (SD 2\u00b72) in the placebo group. Mean change from baseline was -1\u00b71 (SD 2\u00b70) in the gabapentin group and -0\u00b79 (SD 1\u00b78) in the placebo group (adjusted mean difference -0\u00b718 [97\u00b75% CI -0\u00b771 to 0\u00b735]; p=0\u00b745). \n INTERPRETATION: This study was adequately powered, but treatment with gabapentin did not result in significantly lower pain scores in women with chronic pelvic pain, and was associated with higher rates of side-effects than placebo. Given the increasing reports of abuse and evidence of potential harms associated with gabapentin use, it is important that clinicians consider alternative treatment options to off-label gabapentin for the management of chronic pelvic pain and no obvious pelvic pathology. \n Gabapentin not effective for chronic pelvic pain in women. \n Gabapentin not effective for chronic pelvic pain in women \n Is gabapentin effective for chronic pelvic pain?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6056fbfc94d57fd87900001d",
        "question": " We observed differences in the metabolome, proteome, and phytosterol compositions of royal jelly synthesized by nurse bees from multi-pesticide exposed colonies, including significant reductions of key nutrients such as 24-methylenecholesterol, major royal jelly proteins, and 10-hydroxy-2-decenoic acid.  \n  Two-dimensional electrophoresis was used for the fractionation of royal jelly proteins \n the main bioactive compounds of RJ, such as proteins, peptides, fatty acids, and phenolic \n  the expression of four of the major royal jelly proteins (MRJP1, MRJP2, MRJP4, and MRJP5) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid metabolism, transcription and translation, protein folding and binding, olfaction, and learning and memory. \n Does the royal jelly contain proteins?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217c0b63a8413c65300001e",
        "question": "UBE4B might act as an oncogene in regulating RCC development. Therefore it could be served as an effective indicator to predict OS and a potential biomarker for targeted therapy of RCC patients. \n Does UBE4B promote renal cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6025d9e41cb411341a0000b7",
        "question": "Median event-free survival (EFS) and overall survival (OS) for DIPG were 7.8 (95% CI 5.6-8.2) and 10.3 (7.4-13.4) months, and estimated one-year EFS was 12% (2%-31%). Median EFS and OS for HGG were 9.1 (6.4-11) and 12.1 (10-22.1) months, and estimated one-year EFS was 24% (7%-45%).  \n CONCLUSION: Addition of VPA and bevacizumab to radiation was well tolerated but did not appear to improve EFS or OS in children with DIPG or HGG. \n Event-free survival and overall survival of patients not treated with valproic acid were 6.5 and 7.8 months. Accelerated failure time model (a parametric multivariate regression test for time-to-failure data) showed a statistically significant superiority of the median event-free survival of treated patients (6.5 vs. 9.5 months in treated patients; HR 0.54-95 % CI 0.33-0.87; p < 0.05) and also of overall survival (7.8 vs. 13.4 months in treated patients; HR 0.60-95 % CI 0.37-0.98; p = 0.05). \n Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "621b950f3a8413c653000044",
        "question": "All three fibroblast populations were PDGFR\u03b1+/CD34\u00a0+\u00a0but were distinct in their expression of Ngfr/Spon2/Angptl7 (F1), Cxcl14/Smoc2/Rgs2 (F2), and Clec3b/Col14a1/Mmp3 (F3), with potential functions in the regulation of immune responses, response to wounding, and organization of extracellular matrix, respectively. \n Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent bone loss. \n Is SMOC2 expressed during wound healing?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620580afc9dfcb9c0900002f",
        "question": "Atemoya juice significantly inhibited CYP1A2 activity in human liver microsomes, but not the activities of CYP2C9 and CYP3A. In spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a CYP1A2 substrate, in rats.  \n The results indicate that a daily intake of atemoya would not change the pharmacokinetics of CYP1A2 substrates such as phenacetin as well as CYP2C9- and CYP3A-substrate drugs. \n Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f602a3882a024a1000001f",
        "question": "A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. \n PURPOSE OF REVIEW: Cabotegravir (CAB) and rilpivirine (RPV) is the first long-acting injectable antiretroviral therapy (ART) option approved for virologically suppressed adults with HIV-1. In addition, long-acting CAB is a promising agent for HIV preexposure prophylaxis (PrEP).  \n SUMMARY: Clinical trial results support the use of long-acting CAB for HIV PrEP and long-acting CAB and RPV as a switch strategy for adults with HIV-1 who are first virologically suppressed with oral ART.  \n OBJECTIVE: We had previously shown that long-acting cabotegravir (CAB-LA) injections fully protected macaques from vaginal simian HIV (SHIV) infection. \n The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study. \n  Long-acting cabotegravir (CAB LA) is a potential new injectable formulation for human immunodeficiency virus (HIV) PrEP being tested in phase III trials. \n Design and Testing of a Cabotegravir Implant for HIV Prevention. \n Cabotegravir and rilpivirine long-acting injectable antiretroviral therapy for the treatment of HIV-1 infection brings promise of a new mode of delivery and potential solutions to some problems of oral therapy, but also new challenges and unanswered questions. \n Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre-exposure prophylaxis of HIV-1 infection. \n Bictegravir, cabotegravir, dolutegravir, elvitegravir, and raltegravir are members of the latest class of antiretrovirals available to treat human immunodeficiency virus (HIV) infection, the integrase strand transfer inhibitors. \n PURPOSE OF REVIEW: Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence \n Long-acting injectable cabotegravir for the prevention of HIV infection \n BACKGROUND: The HIV Prevention Trials Network (HPTN) 083 trial demonstrated that long-acting cabotegravir (CAB-LA) was more effective than tenofovir disoproxil fumarate-emtricitabine (TDF/FTC) in preventing human immunodeficiency virus (HIV) in cisgender men and transgender women who have sex with \n Areas covered: Here, we review trials of cabotegravir (CAB) as treatment of HIV-1 infection and its potential use as pre-exposure prophylaxis (PrEP) in high risk individuals, including issues around oral lead in and potential resistance emergence. Exper \n frequent dosing. This review focuses on the potential benefits and considerations for the study and use of 2 long-acting injectable agents, cabotegravir (GSK1265744LA, CAB LA) and rilpivirine (TMC278LA, RPV LA), for use as chemoprophylaxis for HIV  \n An evaluation of cabotegravir for HIV treatment and prevention. \n Cabotegravir long-acting for HIV-1 prevention. \n Our findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in HIV-2-prevalent settings. \n Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. \n Long-Acting Cabotegravir for HIV/AIDS Prophylaxis. \n Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. \n Cabotegravir is a novel human immunodeficiency virus integrase enzyme inhibitor used for prevention and treatment of HIV infection. \n PURPOSE OF REVIEW: Long-acting cabotegravir may provide a novel therapeutic option for both the treatment and prevention of HIV-1 infection that does not necessitate adherence  \n Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1. \n Cabotegravir: its potential for antiretroviral therapy and preexposure prophylaxis. \n Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial. \n Is Cabotegravir effective for HIV prevention?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62211b973a8413c65300006c",
        "question": "These observations indicate that 6OTD targets GSCs through G4 stabilization and promotion of DNA damage responses. Therefore, G4s are promising therapeutic targets for glioblastoma. \n Targeting glioma stem cells in vivo by a G-quadruplex-stabilizing synthetic macrocyclic hexaoxazole. \n G-quadruplex (G4) DNA is a type of quadruple helix structure formed by a continuous guanine-rich DNA sequence. Emerging evidence in recent years authenticated that G4 DNA structures exist both in cell-free and cellular systems, and function in different diseases, especially in various cancers, aging, neurological diseases, and have been considered novel promising targets for drug design. \n Therefore, G4s are promising therapeutic targets for glioblastoma. \n Guanine-rich oligonucleotides (GROs) are promising therapeutic candidate for cancer treatment and other biomedical application. \n These findings are valuable to the design and rationale behind the possible targeted drug delivery to specific cellular organelles using GROs. \n The G-quadruplex (G4) DNA, which has been developed as a potential anticancer target in drug screening and design, plays a crucial role in the oncogene transcription and translation. \n Therefore, a novel G4-directed therapeutic strategy could specifically target cancer stem cells in GBM. \n Are G-quadruplexes(G4) possible drug targets for glioblastoma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622608ea3a8413c653000079",
        "question": "RUNX1T1 rs34269950 is associated with obesity and metabolic syndrome. \n Of these SNPs only rs34269950 located in the 'RRACH' motif, the most common N6-methyladenosine (m6A) methylation modification site (recognized by FTO), was significantly associated with obesity risk and metabolic abnormalities. Specifically, compared to AA genotype, rs34269950 del/del genotype was associated with a 1.47 [95% confidence interval (CI): 1.01-2.14, P\u2009=\u20090.042] fold higher rate of obesity risk.  \n Our study demonstrates that RUNX1T1 rs34269950, located in a potential FTO recognition motif, is significantly associated with waist circumference. T \n Is RUNX1T1 associate with obesity?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f9cb19c9dfcb9c09000002",
        "question": "Adamts18 deficiency promotes colon carcinogenesis by enhancing \u03b2-catenin and p38MAPK/ERK1/2 signaling in the mouse model of AOM/DSS-induced colitis-associated colorectal cancer. \n ADAMTS18 is a novel tumor suppressor and is critical to the pathology of human colorectal cancer. However, the underlying mechanism is not clear. Here we generated an Adamts18-deficient mouse strain as an in vivo model to investigate the role of ADAMTS18 in the pathogenesis of colorectal cancer. In AOM/DSS-induced colitis-associated colorectal cancer, the deficiency of Adamts18 in mice resulted in enhanced tumorigenesis and colon inflammation that could be attributed in part to enhanced nuclear translocation of \u03b2-catenin and elevated expression of its downstream target genes, cyclin D1 and c-myc. Moreover, increased p38MAPK and ERK1/2 activities were detected in colon cancer cells from Adamts18-deficient mice. Further studies revealed that ADAMTS18 deficiency reduced intestinal E-cadherin levels in mice, which ultimately led to intestinal barrier dysfunction. These data indicate that Adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated Wnt/\u03b2-catenin and p38MAPK/ERK1/2 signaling and promotes colon cancer in this mouse model. \n Is Adamts18 deficiency associated with cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f5f89b882a024a10000019",
        "question": "Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. \n CONCLUSIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. \n CONCLUSIONS: There was a high rate of continued study participation and long-term benefit with ozanimod HCl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active UC in the TOUCHSTONE OLE. [NCT02531126]. \n Ozanimod: A First-in-Class Sphingosine 1-Phosphate Receptor Modulator for the Treatment of Ulcerative Colitis. \n CONCLUSION: Ozanimod is another option in the growing arsenal of UC treatment. \n RELEVANCE TO PATIENT CARE AND CLINICAL PRACTICE: Ozanimod is the first sphingosine 1-phosphate modulator to be approved for UC and is administered orally. Its efficacy profile is comparable with other UC medications. \n Compared with placebo, ozanimod led to clinical remission in a significantly higher proportion of patients in both the induction and maintenance phase. Additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid-free remission, and mucosal healing, ozanimod performed significantly better than placebo.  \n Ozanimod interferes with migrations of activated T cells to the site of inflammation and is a promising drug for the UC treatment.Key words: Crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis. \n SIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Fund \n The sphingosine-1-phosphate receptor-1 (S1P1) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.  \n Ozanimod (RPC1063) is a specific and potent small molecule modulator of the sphingosine 1-phosphate receptor 1 (S1PR1) and receptor 5 (S1PR5), which has shown therapeutic benefit in clinical trials of relapsing multiple sclerosis and ulcerative colitis. Ozan \n SIONS: Ozanimod was more effective than placebo as induction and maintenance therapy in patients with moderately to severely active ulcerative colitis. (Fun \n SIONS: In this preliminary trial, ozanimod at a daily dose of 1 mg resulted in a slightly higher rate of clinical remission of ulcerative colitis than placebo. The  \n Is Ozanimod effective for Ulcerative Colitis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621bd38d3a8413c653000046",
        "question": "Altered glycoprotein expression has been demonstrated in tissue from patients with Barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.  \n Esophageal adenocarcinoma represents a highly morbid and mortal cancer with a defined progression from metaplasia (Barrett's esophagus) to dysplasia to neoplasia. This disease is highlighted because (1) differences in glycan profiles between the stages of disease progression have been described in the glycoproteomic literature; (2) a glycan biomarker that identifies a given stage may be used as a predictor of disease progression and thus may have significant influence over clinical management; and (3) the differences in glycan profiles between disease and disease-free states in esophageal cancer are more dramatic than in other cancers. \n  comparative glycomic profiling of EAC reveals a subset of glycans that can be selected as candidate biomarkers \n  comparative glycomic profiling of esophageal adenocarcinoma reveals a subset of glycans that can be selected as candidate biomarkers \n IgG glycosylation profile was independently associated with esophageal precancerosis beyond inflammation, which could be an early biomarker for esophageal cancer. \n Is esophageal adenocarcinoma associated with aberrant glycosylation?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622629d13a8413c65300007e",
        "question": "m6A demethylase FTO suppresses pancreatic cancer tumorigenesis by demethylating PJA2 and inhibiting Wnt signaling. \n Moreover, FTO demethylated the m6A modification of praja ring finger ubiquitin ligase 2 (PJA2), thereby reducing its mRNA decay, suppressing Wnt signaling, and ultimately restraining the proliferation, invasion, and metastasis of pancreatic cancer cells. \n Can FTO promote pancreatic cancer development?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "621b8dee3a8413c653000042",
        "question": "lysozyme present in the natural tear \n Lysozyme (Lyz) is a naturally occurring enzyme that operates against Gram-positive bacteria and leads to cell death. This antimicrobial enzyme forms the part of the innate defense system of nearly all animals and exists in their somatic discharges such as milk, tears, saliva and urine. \n tear lysozyme \n lysozyme in tears, saliva, sweat, and other body fluids,  \n In this study we quantify lysozyme, the most prevalent protein in tear fluid,  \n Lysozyme (LZM) is a natural anti-bacterial protein that is found in the saliva, tears and milk of all mammals including humans.  \n Is Lysozyme abundant in human tears?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6052715494d57fd87900000e",
        "question": "FTY720 (Fingolimod) is a known sphingosine-1-phosphate (S1P) receptor agonist that exerts strong anti-inflammatory effects and was approved as the first oral drug for the treatment of multiple sclerosis by the US Food and Drug Administration (FDA) in 2010.  \n Is FTY720 FDA approved?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621d19cc3a8413c65300004a",
        "question": "cytokeratin fragment antigen\u00a021-1 (CYFRA21-1) in patients with laryngeal squamous cell carcinoma (LSCC) and its correlation with tumorigenesis and progression \n  cytokeratin fragment 19 (AUC=0.6882, p<0.0001) proved best in detecting relapse. \n The immunohistochemistry staining for cancer antigen 19-9, carcinoembryonic antigen, cytokeratin 20, and Ki-67 showed comparable intensities in both groups. \n evels of inflammatory and tumor markers, including carbohydrate antigen (CA) 19-9, CA125, carcinoembryonic antigen (CEA), CA153, and cytokeratin 19 fragments (CYFRA21-1),  \n Is cytokeratin a tumor marker?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "602596691cb411341a0000ad",
        "question": "The Janus Kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours M1 macrophage development. \n Tofacitinib, a small JAK inhibitor, is approved for the treatment of RA and has demonstrated good efficacy in psoriasis phase III clinical trials.  \n Is tofacitinib a JAK inhibitor?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "60292dc61cb411341a000110",
        "question": "Poisons are widespread in plants and animals and humankind has often tried to turn them to its own advantage. Owing to their poisonous properties, some species of Strychnos genus have been employed mainly in hunting and fishing, as an adjunct to weapons used not only in the search of food and clothes, but also for preventing depredation by wild animals. They have been employed for martial and criminal purposes and also as a means of determining guilt or innocence. By their nature, poisons such as strychnine and curare affect the functioning of the victim's body;  \n The ethnobotanical uses of South American species of Strychnos L. (Loganiaceae) are reviewed, with the exception of their major r\u00f4le in the preparation of curare, which will be dealt with in detail elsewhere. \n VELOPMENT: Curare is prepared by boiling the roots, bark and stalks of different plants belonging to the Loganiaceae (Strychnos) and Menispermaceae families (Chondrodendron, Curarea and Abuta).  \n The history to about 1850 of the muscle-relaxant poison curare is discussed, especially the developments leading to the botanical identification of the plants that yield the alkaloidal active principles: Loganiaceae (Strychnos species) and Menispermaceae (Abuta, Chondrodendron, and Curarea species). \n or centuries. The study reviews the historical and ethnographic aspects of the use of curares and timb\u00f3s in the Amazonian region.DEVELOPMENT: Curare is prepared by boiling the roots, bark and stalks of different plants belonging to the Loganiaceae (Strychnos) and Menispermaceae families (Chondrod \n \u0391re plants from the genus Strychnos the original source of curare?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f9605f882a024a1000004f",
        "question": "Missense variants in the N-terminal domain of the A isoform of FHF2/FGF13 cause an X-linked developmental and epileptic encephalopathy. \n Whole-exome sequencing identified hemi- and heterozygous variants in the N-terminal domain of the A isoform of FHF2 (FHF2A). The X-linked FHF2 gene (also known as FGF13) has alternative first exons which produce multiple protein isoforms that differ in their N-terminal sequence. The variants were located at highly conserved residues in the FHF2A inactivation particle that competes with the intrinsic fast inactivation mechanism of Nav channels. Functional characterization of mutant FHF2A co-expressed with wild-type Nav1.6 (SCN8A) revealed that mutant FHF2A proteins lost the ability to induce rapid-onset, long-term blockade of the channel while retaining pro-excitatory properties. These gain-of-function effects are likely to increase neuronal excitability consistent with the epileptic potential of FHF2 variants. Our findings demonstrate that FHF2 variants are a cause of infantile-onset developmental and epileptic encephalopathy and underline the critical role of the FHF2A isoform in regulating Nav channel function. \n Are variants in FHF2 (also known as FGF13) associated with encephalopathy?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "602c26171cb411341a000122",
        "question": "AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. \n AZD9668 is a reversible and selective inhibitor of NE, well tolerated at doses of 60 mg bid during Phase I/IIa development. \n Is AZD9668 a VEGF mRNA drug?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "603400051cb411341a00014e",
        "question": "Reciprocal H3.3 gene editing identifies K27M and G34R mechanisms in pediatric glioma including NOTCH signaling. \n Well-known oncohistones, with mutations on both H3.1 and H3.3, include H3K36M in chondroblastoma, H3K27M in glioma \n Diffuse intrinsic pontine gliomas (DIPG) are the most aggressive brain tumors in children with 5-year survival rates of only 2%. About 85% of all DIPG are characterized by a lysine-to-methionine substitution in histone 3, which leads to global H3K27 hypomethylation accompanied by H3K27 hyperacetylation.  \n Is histone variant H3.3K27M associated with gliomas?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6081a83f4e6a4cf630000007",
        "question": "Hsp90 co-chaperones Pp5 and FKBPs \n The co-chaperone FK506-binding protein 51 (FKBP51) \n co\u2011chaperone FKBP52  \n Is FKBP52 encoding a chaperone ?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62004357c9dfcb9c09000015",
        "question": "\u03b1CGRP, another amyloidogenic member of the CGRP family. \n Therefore, in this work, we investigated the amyloidogenic profile of \u03b1CGRP, a 37-residue-long peptide hormone, utilizing both biophysical experimental techniques and Molecular Dynamics simulations. These efforts unravel a novel amyloidogenic member of the CGRP family and provide insights into the mechanism underlying the \u03b1CGRP polymerization. \n Does \u03b1CGRP have amyloidogenic properties?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "60282c3f1cb411341a0000fe",
        "question": "CONCLUSIONS: Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting.  \n Is istiratumab effective for pancreatic cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "601efda31cb411341a000069",
        "question": "bleomycin-induced pulmonary fibrosis \n bleomycin (BLM)-induced pulmonary  \n Pulmonary toxicity is a devastating complication of bleomycin chemotherapy.  \n Bleomycin containing regimen is routinely employed in the treatment of HL. Pulmonary toxicity due to this drug is the most feared side effect in these regimens where the mortality rate is approximately 2%-3%.  \n Bleomycin might cause pulmonary fibrosis at higher cumulative doses as toxic effect directly to the lungs or most likely in addition by the formation of vascular microthrombi. \n The comparative pulmonary toxicity induced by bleomycin and talisomycin (former trivial name: tallysomycin A) was evaluated by measuring lung hydroxyproline content. \n Clinicians should always remember that bleomycin toxicity may lead to fatal complications in patients with comorbid conditions. \n CONTEXT: The application of bleomycin is limited due to its side effects including lung toxicity. \n Bleomycin is an antineoplastic agent that causes a dose-related lung fibrosis that limits its therapeutic effectiveness. \n Acute Lung Toxicity After Intralesional Bleomycin Sclerotherapy. \n We report a case of a severe acute lung toxicity after a low dose of a second bleomycin intralesional injection in a 5-year-old girl. \n Renal damage, following cisplatin administration, with subsequent accumulation of bleomycin was the likely cause of the high lung toxicity. \n Whenever possible, bleomycin should precede cisplatin infusion to minimize the risk of lung toxicity. \n The most severe form of BLM-induced pulmonary toxicity is lung fibrosis. \n Results from this study suggest that an excess production of superoxide anions by alveolar macrophages may be the underlying cause of bleomycin pulmonary toxicity. \n Bleomycin lung toxicity is well established and can manifest as bleomycin-induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications. \n High doses of bleomycin administered to patients with lymphomas and other tumors lead to significant lung toxicity in general, and to apoptosis of epithelial cells, in particular.  \n sis of bleomycin-induced lung toxicity is based on the combination of clinical and radiological features, and requires to rule out differential diagnoses including pneumocystis. \"Bleo \n Doxorubicin, bleomycin, vinblastine sulfate, and dacarbazine (ABVD) is associated with severe toxicity in older patients, particularly from bleomycin-induced lung toxicity (BLT). Ther \n s studies have proposed that the lung toxicity caused by bleomycin is related to the C-terminal regions of these drugs, which have been shown to closely interact with DNA in metal-bleomycin-DNA complexes. Some o \n OBJECTIVES: Bleomycin, etoposide, and cisplatin (BEP) is the most common and successful chemotherapy regimen for germ-cell tumor (GCT) patients, accompanied by a bleomycin-induced dose-dependent lung toxicity in certain pat \n e been no respiratory problems attributable to bleomycin lung toxicity in this study compared with four (3 associated with patient deaths) seen in 91 previously treated patients. The relat \n Mechanisms of bleomycin-induced lung damage. \n Previous studies have proposed that the lung toxicity caused by bleomycin is related to the C-terminal regions of these drugs, which have been shown to closely interact with DNA in metal-bleomycin-DNA complexes. \n g V30 cutoff value of 32% was estimated.CONCLUSION: Bleomycin and RT may cause lung injury  \n Postmortem lung studies were performed in all six patients and revealed findings compatible with bleomycin-induced lung toxicity. \n However, the cytotoxic effects of bleomycin cause a number of adverse responses, in particular in the lung and the skin. \n Bleomycin, a widely used anti-cancer drug, may give rise to pulmonary fibrosis, a serious side effect which is associated with significant morbidity and mortality. \n Bleomycin is a cancer therapeutic known to cause lung injury which progresses to fibrosis. \n and repair. Bleomycin pulmonary toxicity is mediated, at least in part, by the generation of active oxy \n This report suggests that bleomycin lung toxicity may be reversible if treated aggressively. \n Although all bleomycin-treated animals had some evidence of lung toxicity, histologic examination of the lungs revealed markedly reduced bleomycin toxicity in the rats exposed to hypoxia. \n Low temperature inhibits bleomycin lung toxicity in the rat. \n Results at day 22, 3 wk after bleomycin treatment, showed that airway delivery of liposomes before and after intratracheal administration of bleomycin significantly reduced bleomycin-induced lung toxicity as evidenced by less body weight loss, chronic lung inflammation, and fibrosis as well as improved lung compliance compared with controls. \n Protective effect of hypoxia on bleomycin lung toxicity in the rat. \n N-acetyl cysteine (NAC) has recently been shown to have antioxidant properties, and since bleomycin produces pulmonary damage via free oxygen radical toxicity, the possible protective effect of NAC on bleomycin lung toxicity was investigated. \n All rats treated with bleomycin only had typical changes of bleomycin lung toxicity whereas the animals treated with bleomycin and NAC had minimal pathology. \n atic compliance on day 15 was severely decreased with bleomycin alone and showed a further significant decrease when granulocyte colony-stimulating factor was added (controls, 3.85 +/- 0.14 mL/kPa; bleomycin, 1.44 +/- 0.06 mL/kPa; and bleomycin + granulocyte colony-stimulating factor, 0.65 +/- 0.09 mL/kPa; control vs. bleomycin, p <.0001; and bleomycin vs. bleomycin + granulocyte colony-stimulating factor, p =.0003). Lung m \n Bleomycin sometimes causes fatal pulmonary toxicity, including bleomycin-induced pneumonitis. \n Bleomycin is an antineoplastic agent causing fatal pulmonary toxicity. \n Pulmonary toxicity is an important adverse effect of bleomycin treatment. \n Pulmonary toxicity is the most significant complication of bleomycin administration. \n It is possible, however, that the low incidence of clinically significant and fatal pulmonary toxicity, as experienced in this group of patients, may be related to the infusion of bleomycin. \n Bleomycin-mediated pulmonary toxicity: evidence for a p53-mediated response. \n Occurrence of bleomycin lung toxicity requires an immediate and often permanent discontinuation. \n All three developed bleomycin induced pulmonary toxicity in the form of pulmonary fibrosis during treatment of the disease. \n One of the fatal side effect of bleomycin is pulmonary toxicity. \n Pulmonary Toxicity of Bleomycin - A Case Series from a Tertiary Care Center in Southern India. \n Bleomycin is potentially capable of inducing a diffuse interstitial fibrosis of the lung, the pathogenesis of which has not yet been elucidated. \n Intratracheal instillation of bleomycin 1.5 mg resulted in a severe pneumonitis with influx of inflammatory cells into the alveoli as assessed by alveolar lavage, oedema of the alveolar walls, and up to an eight fold increase in the total pulmonary extravascular albumin space, maximal at 72 hours. \n Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats. \n Bleomycin is a highly effective antitumor agent, but pulmonary toxicity, characterized by an acute inflammatory reaction and associated pulmonary edema, limits clinical use of the drug. \n In this study we investigated bleomycin-induced pulmonary toxicity in patients with germ-cell tumour by means of technetium-99m diethylene triamine penta-acetic acid aerosol scintigraphy. \n Does bleomycin cause lung toxicity?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6082f4374e6a4cf63000000f",
        "question": "Keutel syndrome (OMIM 245150) is a very rare syndrome  \n Keutel syndrome is a rare autosomal-recessive condition characterized by abnormal cartilage calcification. \n MGP-deficiency in humans leads to Keutel syndrome, a rare genetic disease hallmarked by abnormal soft tissue calcification.  \n Is Keutel syndrome a common genetic disorder?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "601d724a1cb411341a000035",
        "question": "Invasive infections with Fusobacterium necrophorum including Lemierre's syndrome: an 8-year Swedish nationwide retrospective study. \n Lemierre's syndrome is defined as an oropharyngeal infection due to Fusobacterium necrophorum, \n Lemierre's syndrome is a rare but life-threatening condition characterized by an oropharyngeal infection typically secondary to Fusobacterium necrophorum resulting in septic thrombophlebitis of the internal jugular vein.  \n  Lemierre's syndrome is a rare condition that results from oropharyngeal infection with the gram-negative, anaerobic Fusobacterium necrophorum. \n INTRODUCTION: Like Fusobacterium necrophorum, Fusobacterium nucleatum is capable causing Lemierre's syndrome. \n [Lemierre syndrome variant: Hepatic abscesses and hepatic venous thrombosis due to Fusobacterium nucleatum septicemia]. \n Fusobacterium necrophorum-induced sepsis: an unusual case of Lemierre's syndrome. \n F necrophorum is most commonly associated with Lemierre's syndrome: a septic thrombophlebitis of the internal jugular vein. \n Fusobacterium necrophorum Septicemia Leading to Lemierre's Syndrome in an Immunocompetent Individual: A Case Report. \n We present a case of a patient with Lemierre's syndrome caused by Fusobacterium necrophorum who developed a right frontal lobe brain abscess. \n Lemierre's syndrome secondary to Fusobacterium necrophorum infection, a rare cause of hepatic abscess. \n Lemierre's syndrome is an uncommon complication of pharyngitis commonly associated with an anaerobic gram negative bacterium, Fusobacterium necrophorum. \n The following presentation is a case of Lemierre's syndrome in a 23-year-old healthy individual who is infected by a rare species: Fusobacterium nucleatum. \n However, Fusobacterium species causing Lemierre's variant gastrointestinal syndrome has only been reported in case reports. \n Fusobacterium species is known for being a causative agent for Lemierre's syndrome, which is characterized by thrombophlebitis of the jugular vein. \n The Fusobacterium species is known for its association with septic thrombophlebitis of the internal jugular vein (Lemierre's syndrome). Lemierre's syndrome is as \n Lemierre's syndrome due to Fusobacterium necrophorum. \n Fusobacterium species are well described as the causative pathogen in Lemierre's syndrome, a suppurative thrombophlebitis of the jugular vein. However, they are less r \n Introduction: Lemierre's syndrome is a rare but serious complication of an oral infection mostly related to Fusobacterium necrophorum. This condition combines j \n Fusobacterium necrophorum is a gram-negative anaerobic bacterium that is the causative agent of the invasive disease Lemierre's syndrome. \n INTRODUCTION: Lemierre's syndrome is defined as an oropharyngeal infection due to Fusobacterium necrophorum, associated with septic thrombophlebitis of the internal  \n Fusobacterium nucleatum is a gram-negative bacillius commonly found in oropharynx and is traditionally associated with Lemierre syndrome, which is characterized by history of recent oropharyngeal infection, internal jugular vein thrombosis, and isolation of anaerobic pathogens, mainly Fuosobacterium necrophorum. Ho \n Lemierre's syndrome is an uncommon complication of pharyngitis commonly associated with an anaerobic gram negative bacterium, Fusobacterium necrophorum.  \n Fusobacterium species is known for being a causative agent for Lemierre's syndrome, which is characterized by thrombophlebitis of the jugular vein.  \n Lemierre's syndrome is a systemic complication commonly caused by oropharyngeal infection by Fusobacterium species, which manifests itself as an internal jugular vein thrombosis formation.  \n Lemierre's syndrome is a rare but serious condition, characterized by disseminated infection with Fusobacterium necrophorum, most often originating from the oropharynx. T \n Lemierre's syndrome is a rare clinical condition that generally develops secondary to oropharyngeal infection caused by Fusobacterium necrophorum, which is an anaerobic bacteria.  \n Lemierre's syndrome, a systemic anaerobic infection caused by Fusobacterium necrophorum, is characterized by an acute oropharyngeal infection, septic thrombophlebitis of the internal jugular veins, sepsis, and multiple metastatic infections. It c \n Lemierre's syndrome, a systemic anaerobic infection caused by Fusobacterium necrophorum, is characterized by an acute oropharyngeal infection, septic thrombophlebitis of the internal jugular vein, sepsis, and multiple metastatic infections. It c \n Fusobacterium necrophorum is a rare infection most notable for causing Lemierre's syndrome. \n We present a patient with an atypical presentation of Fusobacterium infection, the genus responsible for Lemierre's syndrome. \n INTRODUCTION: Like Fusobacterium necrophorum, Fusobacterium nucleatum is capable causing Lemier \n Fusobacterium necrophorum, a well\u2010known cause of Lemierre's syndrome, was identified. \n We report an unusual case of Lemierre's syndrome due to a rare species of Fusobacterium, that is,\u00a0Fusobacterium nucleatum preceded by Mycoplasma pneumoniae pharyngitis and followed later by\u00a0Epstein-Barr virus infectious mononucleosis. \n We present a case of invasive Fusobacterium infection that meets all criteria for Lemierre syndrome except lacking internal jugular thrombosis. \n Fusobacterium necrophorum is ananaerobic Gram-negative bacillus and is the most common organism reported to cause Lemierre's syndrome which usually occurs one to three weeks post pharyngitis or oropharyngeal surgery. \n Lemierre's disease: postanginal bacteremia and pulmonary involvement caused by Fusobacterium necrophorum. \n Increased diagnosis of Lemierre syndrome and other Fusobacterium necrophorum infections at a Children's Hospital. \n The Fusobacterium species is known for its association with septic thrombophlebitis of the internal jugular vein (Lemierre's syndrome). \n Fusobacterium species have rarely been implicated in cases of gastrointestinal variant of Lemierre's syndrome. \n Fusobacterium species are well described as the causative pathogen in Lemierre's syndrome, a suppurative thrombophlebitis of the jugular vein. \n F. necrophorum is unique among non-spore-forming anaerobes, first for its virulence and association with Lemierre's syndrome as a monomicrobial infection and second because it seems probable that it is an exogenously acquired infection. \n Fusobacteria are most often associated with the classic presentation of Lemierre's syndrome consisting of a sore throat, internal jugular vein thrombophlebitis, and septic emboli to the lungs. \n Fusobacterium necrophorum plays a causal role in a rare and life-threatening condition, Lemierre's syndrome. \n Lemierre's syndrome is a rare disorder of young adults caused by the anaerobic bacterium, Fusobacterium necrophorum and occasionally by other Fusobacterium species (F. nucleatum, F. mortiferum and F. varium etc). \n Lemierre's syndrome is a severe complication of Fusobacterium necrophorum oropharyngeal infection associated with metastatic foci of infection, internal jugular vein thrombosis, and septicemia. \n Short blood culture time-to-positivity in Fusobacterium necrophorum bacteremia is associated with Lemierre's syndrome. \n The causative organisms are the anaerobic fusobacteria, most commonly Fusobacterium necrophorum. \n In a 3-year prospective study, all cases of disseminated Fusobacterium necrophorum infections found in Denmark from 1998 to 2001 were analysed, with the aim of describing the epidemiology and clinical features of the variants of Lemierre's syndrome and disseminated non-head-and-neck-associated F. necrophorum infections. \n Is fusobacterium associated with Lemierre's syndrome?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621fd6083a8413c653000066",
        "question": "Mapping the position and quantifying the level of 5-methylcytosine (m5C) as a modification in different types of cellular RNA is an important objective in the field of epitranscriptomics. \n N6-methyladenosine (m6A) is the most abundant internal modification on messenger RNAs (mRNAs) and long noncoding RNAs (lncRNAs) in eukaryotes \n Gluten-induced RNA methylation changes regulate intestinal inflammation via allele-specific XPO1 translation in epithelial cells. \n nogaster was methylated to a lower degree, but in the case of Dictyostelium, there was no difference in the methylation of RNA isolated from wild-type and Dnmt2 knock-out strains. Meth \n The detection and quantification of methylated RNA can be beneficial to understand certain cellular regulation processes such as transcriptional modulation of gene expression, immune response, or epigenetic alterations.  \n ombined genetic and biochemical approach revealed that human DNMT2 did not methylate DNA but instead methylated a small RNA; mass spectrometry showed that this RNA is aspartic acid transfer RNA (tRNA(Asp)) and that DNMT2 specifically methylated cytosine 38 in the anticodon loop. The \n ted nucleosides in naturally occurring RNA are also methylated or otherwise modified, but the immunomodulatory effects of these alterations remain untested. We s \n -induced loss of RNA methylation seemed specific for DNMT2 target sites because we did not observe any significant demethylation at sites known to be methylated by other RNA methyltransferases. Our results  \n Crude extracts of this organism possess RNA methylase activity but no detectable DNA methylase activity. \n A combined genetic and biochemical approach revealed that human DNMT2 did not methylate DNA but instead methylated a small RNA; mass spectrometry showed that this RNA is aspartic acid transfer RNA (tRNA(Asp)) and that DNMT2 specifically methylated cytosine 38 in the anticodon loop. \n Here, we propose that RNA methylation began prior to DNA methylation in the early forms of life evolving on Earth. \n Unlike DNA, RNA is not methylated, yes or no?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "620155b6c9dfcb9c09000024",
        "question": "Disruption of nuclear architecture as a cause of COVID-19 induced anosmia. \n Here, using molecular evaluation of human olfactory epithelium (OE) from subjects succumbing to COVID-19 and a hamster model of SARS-CoV-2 infection, we discovered widespread downregulation of olfactory receptors (ORs) as well as key components of their signaling pathway. OR downregulation likely represents a non-cell autonomous effect, since SARS-CoV-2 detection in OSNs is extremely rare both in human and hamster OEs. A likely explanation for the reduction of OR transcription is the striking reorganization of nuclear architecture observed in the OSN lineage, which disrupts multi-chromosomal compartments regulating OR expression in humans and hamsters. Our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of COVID-19. \n Is covid-19 induced anosmia caused by disruption of nuclear architecture?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622dd1433a8413c6530000a5",
        "question": "\u0391lpha-Taxilin (\u03b1-Taxilin) has been found as one of the novel, significantly up regulated protein in RA \n Expression of \u03b1-taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.  \n \u03b1-Taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.  \n Expression of \u03b1-taxilin in hepatocellular carcinoma correlates with growth activity and malignant potential of the tumor. \n Is taxilin a cancer marker?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622668313a8413c653000087",
        "question": "In this work, we investigated the role and regulatory mechanism of lncRNA prostate cancer-associated transcript 6 (PCAT6) in breast cancer progression. \n Is PCAT6 a microRNA?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6201a4edc9dfcb9c09000028",
        "question": "HDAC1 is required for GATA-1 transcription activity, global chromatin occupancy and hematopoiesis. \n GATA-12RA knock-in (KI) mice suffer mild anemia and thrombocytopenia with accumulation of immature erythrocytes and megakaryocytes in bone marrow and spleen. Single cell RNA-seq analysis of Lin- cKit+ (LK) cells further reveal a profound change in cell subpopulations and signature gene expression patterns in HSC, myeloid progenitors, and erythroid/megakaryocyte clusters in KI mice. Thus, GATA-1 deacetylation and its interaction with HDAC1 modulates GATA-1 chromatin binding and transcriptional activity that control erythroid/megakaryocyte commitment and differentiation. \n Is HDAC1 required for GATA-1 transcriptional activity?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "623a24d6f0baec9a1b000002",
        "question": "Telomestatin is a natural product isolated from Streptomyces anulatus 3533-SV4 and has been shown to be a very potent telomerase inhibitor. \n Telomestatin, a potent telomerase inhibitor that interacts quite specifically with the human telomeric intramolecular g-quadruplex. \n Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095),  \n  G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), \n  We found that treatment with telomestatin reproducibly inhibited telomerase activity in the BCR-ABL-positive leukemic cell lines \n A novel telomerase inhibitor, telomestatin, isolated from Streptomyces anulatus is the most potent telomerase inhibitor so far. \n Telomerase inhibitor, telomestatin, a specific mechanism to interact with telomere structure \n Telomestatin specifically inhibited telomerase without affecting reverse transcriptases and polymerases. \n In addition, telomestatin induced telomere shortening, but its ratio was extremely faster than that observed in physiological telomere shortening. \n A novel telomerase inhibitor, telomestatin, isolated from Streptomyces anulatus is the most potent telomerase inhibitor so far.  \n ructure has been yet resolved for the complex with telomestatin, one of the most promising G-quadruplex-targeting anticancer drug candidates. Here \n Telomestatin, a strong telomerase inhibitor with G-quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers. \n Thus, telomestatin provide the novel therapeutic molecular target for cancer chemotherapy. \n Telomerase inhibition with a novel G-quadruplex-interactive agent, telomestatin: in vitro and in vivo studies in acute leukemia. \n Activity of a novel G-quadruplex-interactive telomerase inhibitor, telomestatin (SOT-095), against human leukemia cells: involvement of ATM-dependent DNA damage response pathways. \n Is telomestatin, a novel statin drug used to treat high cholesterol?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f7d4da882a024a10000033",
        "question": "AstraZeneca COVID-19 vaccine and Guillain- Barr\u00e9 Syndrome in Tasmania: A causal link? \n Nearly all reported cases of post-COVID-19 vacciation inflammatory demyelinating polyneuropathy are linked to AstraZeneca vaccination and a variant with bifacial weakness is the most reported form of GBS globally. \n Guillain-Barr\u00e9 Syndrome Presenting as Facial Diplegia after COVID-19 Vaccination: A Case Report. \n CASE REPORT: We report a case of atypical GBS occurring after Coronavirus disease 2019 (COVID-19) vaccination in an otherwise healthy 38-year-old man. \n It is critical for emergency physicians to be aware of the manifold presentations of GBS for early recognition and treatment. This may be of particular importance in the context of a worldwide vaccination campaign in response to the COVID-19 pandemic. \n Guillain-Barr\u00e9 syndrome following ChAdOx1 nCoV-19 COVID-19 vaccination: A case series. \n We report three patients who developed Guillain-Barr\u00e9 syndrome following ChAdOx1 nCoV-19 vaccination, who did not have active or prior COVID-19 infection.  \n We report a case of Guillain-Barr\u00e9\u00a0syndrome (GBS) following the first dose of Oxford/AstraZeneca COVID-19 vaccine with papilledema as atypical onset. \n We report a case of Guillain-Barr\u00e9 syndrome (GBS) occurring soon after the first dose of Vaxzevria (previously known as COVID-19 vaccine AstraZeneca). \n Guillain-\u200bBarr\u00e9 Syndrome Associated with COVID-19 Vaccination \n Guillain-\u200bBarr\u00e9 Syndrome Associated with COVID-19 Vaccination. \n To date, cases of Guillain-Barr\u00e9 syndrome (GBS) following a COVID vaccine (Pfizer, Johnson & Johnson, Janssen, AstraZeneca) have been reported. \n Case of Guillain-Barr\u00e9 syndrome following COVID-19 vaccine. \n We report a case of Guillain-Barr\u00e9 syndrome after the first dose of SARS-CoV-2 vaccine and believe this is a temporal, rather than causal association. \n COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. \n Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barr\u00e9 Syndrome, February-July 2021. \n Guillain-Barr\u00e9 syndrome associated with Covid-19: A close relationship or just a coincidence? (Review). \n Relation between COVID-19 and Guillain-Barr\u00e9 syndrome in adults. Systematic review. \n Guillain-Barr\u00e9 syndrome after COVID-19 vaccination. \n Is there an association between Guillain\u2013Barr\u00e9 syndrome and covid vaccine?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61fa904fc9dfcb9c09000004",
        "question": "BACKGROUND: High-dose erythropoietin has been shown to have a neuroprotective effect in preclinical models of neonatal brain injury, and phase 2 trials have suggested possible efficacy; however, the benefits and safety of this therapy in extremely preterm infants have not been established. \n There was no significant difference between the erythropoietin group and the placebo group in the incidence of death or severe neurodevelopmental impairment at 2 years of age (97 children [26%] vs. 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P\u2009=\u20090.80). There were no significant differences between the groups in the rates of retinopathy of prematurity, intracranial hemorrhage, sepsis, necrotizing enterocolitis, bronchopulmonary dysplasia, or death or in the frequency of serious adverse events.CONCLUSIONS: High-dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe neurodevelopmental impairment or death at 2 years of age. \n Based on existing evidence, it is still too early to recommend Epo as the standard treatment for preterm brain injury. \n Erythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials; however, long-term follow-up of these infants is needed to come to definite conclusions. \n Is Erythropoietin effective for neuroprotection of Preterm Infants.",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6226317a3a8413c653000080",
        "question": "Ameloblastoma is a benign odontogenic tumor which undergoes malignant transformation to ameloblastic carcinoma.  \n Ameloblastomas are benign tumors that most commonly affecting the mandible.  \n Ameloblastoma is a neoplasm arising in the craniofacial skeleton. \n Ameloblastoma is an invasive odontogenic tumor, and for reconstruction, i \n Ameloblastoma is a locally aggressive, benign epithelial odontogenic neoplasm currently classified to include conventional, unicystic, and extraosseous/peripheral subtypes.  \n Ameloblastoma (AM) is a slow growing and aggressive benign tumor with an odontogenic epithelial origin arising from the mandible or maxilla. \n The ameloblastoma is a benign but aggressive neoplasm of odontogenic origin. \n Ameloblastoma is a rare odontogenic tumor of the jaw. \n Ameloblastoma is the most common epithelial odontogenic tumor. \n Ameloblastoma or adamantinoma is the rarest of the three forms of tumor of the odontogenic type. \n Ameloblastoma is a benign locally invasive odontogenic tumor. \n Ameloblastoma is the second most common benign epithelial odontogenic tumor and though it is of a benign nature, it is locally invasive, has a high recurrence rate and could potentially become malignant. \n BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-facial region. \n Ameloblastoma is the most common odontogenic tumor of epithelial origin, and though it is of a benign nature, it frequently infiltrates the bone, has a high rate of recurrence and could potentially become malignant. \n OBJECTIVES: Ameloblastoma is a benign, slow-growing, locally invasive epithelial tumor of odontogenic origin, with unlimited growth capacity and a strong tendency to recur. \n Ameloblastoma, a benign but locally aggressive odontogenic tumor, often demonstrates metastasis despite benign histological features and this variant is termed as metastasizing ameloblastoma (METAM).  \n Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification. AC \n BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-fac \n Peripheral ameloblastoma is a benign odontogenic tumor with the same histological characteristics as the centrally located ameloblastoma, but appearing in the gingiva and mucosa of the tooth-bearing area of the jaws. \n BACKGROUND Ameloblastoma (AB) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence. \n Ameloblastoma(AB) is an aggressive and slow-growing tumor with high recurrence rate, which arises from odontogenic epithelium. \n Ameloblastoma (AB) is the most common benign epithelial odontogenic tumor occurring in the jawbone. \n or growth. Ameloblastoma (AB) is a relatively common odontogenic epithelial neoplasm that manifests local infiltrative intraosse \n Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification. \n Ameloblastoma is a benign epithelial odontogenic tumor that typically arises in the mandible or maxilla or, rarely, in the immediate adjacent soft tissues \n nic epithelial components with a mature fibrous stroma. It is the second most common odontogenic neoplasm following odontome. Acanthomatous ameloblast \n OBJECTIVE AND IMPORTANCE: Ameloblastoma is a locally aggressive benign tumor, commonly occurring in the mandible \n BACKGROUND AND OVERVIEW: Ameloblastoma is an odontogenic tumor predominantly occurring in patients who are in their 20s and 30s \n BACKGROUND: The ameloblastoma is the most common odontogenic epithelial tumor, which belong to benign neoplasms that present a painless course, and usually occur in the oromaxillo-facial region \n BACKGROUND: Ameloblastoma is a neoplasm classified as a benign epithelial odontogenic tumor of the jaws, grow slowly and are locally invasive \n BACKGROUND: Ameloblastoma is a frequent odontogenic benign tumor characterized by local invasiveness, high risk of recurrence and occasional metastasis and malignant transformation \n BACKGROUND: Ameloblastoma is a rare benign odontogenic tumor with locally aggressive behavior and a high recurrence rate \n BACKGROUND: Ameloblastoma is a benign odontogenic tumor, exhibiting local invasiveness and high rate of recurrence \n BACKGROUND: Ameloblastoma is a rare benign odontogenic tumor with a metastasis rate estimated at 2% of cases, mainly involving the lung (80%) and lymph nodes (20%).METHODS: We hereby present the case of a 26 year old patient with a history of locally recurrent mandibular ameloblastoma who developed a temporal intracranial ameloblastoma tumor requiring a collaborative neurosurgical and maxillo-facial radical surgical approach.CONCLUSION: Although ameloblastomas are histologically benign, the temporal topography questions the dissemination pathophysiology of the tumor (metastasis or local extension through temporal muscle fibers), mainly relevant  \n Ameloblastoma is a histologically benign tumor derived from odontogenic apparatus. \n BACKGROUND: Ameloblastoma is a benign odontogenic tumour that may exhibit aggressive biological behaviour with local recurrence and metastasis following initial surgica \n Ameloblastomas are histologically benign tumors derived from the odontogenic apparatus. \n Ameloblastoma is a benign odontogenic tumor generally present in the jaw bone. \n Ameloblastoma is a locally aggressive tumor derived from odontogenic epithelium. \n Ameloblastoma is the most common clinically significant epithelial odontogenic tumor, and is considered a benign but locally aggressive tumor of the craniofacial region. \n Ameloblastoma (AB), which is the most common odontogenic tumor, may originate from the dental lamina remnants. \n Is Ameloblastoma (AB) a common benign tumor occurring in the brain?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "622901d23a8413c65300008c",
        "question": "Ameloblastic carcinoma (AC) is defined as a rare primary epithelial odontogenic malignant neoplasm and the malignant counterpart of benign epithelial odontogenic tumor of ameloblastoma (AB) by the WHO classification \n AC develops pulmonary metastasis in about one third of the patients and reveals a poor prognosis \n Ameloblastomas are benign but locally invasive neoplasms which may grow to massive proportions and cause significant morbidity. Although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat. \n Ameloblastoma of the maxilla is a rare odontogenic tumor that rarely metastasizes. \n Ameloblastoma is an odontogenic tumor, usually benign, which rarely metastasizes to distant organs. \n Although ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity. \n The World Health Organization (WHO) has defined malignant ameloblastoma (MA) as a histologically benign-appearing ameloblastoma that has metastasized. \n Distant metastasis is a very rare condition and is designated as metastasizing (malignant) ameloblastoma despite its benign histological appearance. \n Ameloblastoma is a locally invasive, histologically nonmalignant tumor that may on very rare occasions give rise to metastases. \n Is Ameloblastoma (AB) a benign tumor that never metastasizes?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "620157bec9dfcb9c09000025",
        "question": "Chromatin conformation capture using in situ Hi-C on fluorescence-activated cell-sorted olfactory sensory neurons and their progenitors shows that olfactory receptor gene clusters from 18 chromosomes make specific and robust interchromosomal contacts that increase with differentiation of the cells. These contacts are orchestrated by intergenic olfactory receptor enhancers, the 'Greek islands', which first contribute to the formation of olfactory receptor compartments and then form a multi-chromosomal super-enhancer that associates with the single active olfactory receptor gene. The Greek-island-bound transcription factor LHX2 and adaptor protein LDB1 regulate the assembly and maintenance of olfactory receptor compartments, Greek island hubs and olfactory receptor transcription, providing mechanistic insights into and functional support for the role of trans interactions in gene expression. \n Is there any role of the 'Greek islands' in olfactory receptor choice?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622dc4b63a8413c6530000a4",
        "question": "Western blotting assays presented upregulated expressions of TNF receptor-activating factor 6 (TRAF6) and integrin \u03b23 induced by gingipains and RANKL compared to RANKL alone. Enhanced integrin-related signaling was also demonstrated by elevated phosphorylations of FAK and paxillin compared to control. Moreover, the pit resorption assays showed that gingipains augmented bone resorptive function of osteoclasts induced by RANKL.  \n paxillin levels induced by RANKL in murine bone marrow cells. \n RANKL promotes paxillin serine and tyrosine phosphorylation, \n Is paxillin affected by RANKL?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622b95dc3a8413c653000092",
        "question": "Systematic Quantification of Neurotrophic Adipokines RBP4, PEDF, and Clusterin in Human Cerebrospinal Fluid and Serum. \n Retinol-binding protein 4 (RBP4) is a prominent adipokine i \n Fetuin-A and retinol-binding protein 4 (RBP4) are secreted as both hepatokine and adipokine.  \n Is retinol binding protein 4 an adipokine?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622ce21d3a8413c65300009c",
        "question": "Hydin was recently identified as an axonemal protein; however, its function is as yet unknown. \n precise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility. \n Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621e62c33a8413c653000050",
        "question": "spiralize: an R package for Visualizing Data on Spirals. \n Spiral layout has two major advantages for data visualization. First, it is able to visualize data with long axes, which greatly improves the resolution of visualization. Second, it is efficient for time series data to reveal periodic patterns. Here we present the R package spiralize that provides a general solution for visualizing data on spirals. spiralize implements numerous graphics functions so that self-defined high-level graphics can be easily implemented by users. The flexibility and power of spiralize are demonstrated by five examples from real-world datasets. \n Are there any R packages that help with visualizing data on spirals?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61faa3bac9dfcb9c0900000b",
        "question": "During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P\u2009=\u20090.84).CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa despite previous evidence of immunogenicity. (HVTN 702 ClinicalTrials.gov number, NCT02968849.). \n The advanced-phase HIV prevention vaccine trials done in South Africa (HVTN 702) and in Thailand (RV144), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results. The South African trial did not find vaccine efficacy, whereas the Thai trial had modest, but statistically significant, success with the modified intention-to-treat analysis prespecified in the protocols of both studies.  \n However, with the recent failure of the HVTN 702 clinical trial, comprehensive profiling of humoral immune responses may provide insight for these disappointing results.  \n A canarypox-protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing infection in Thailand. \n e vaccine and placebo groups. During the 24-month follow-up, HIV-1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group (hazard ratio, 1.02; 95% confidence interval, 0.81 to 1.30; P\u2009=\u20090.84).CONCLUSIONS: The ALVAC-gp120 regimen did not prevent HIV-1 infection among participants in South Africa d \n Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "622baf3f3a8413c653000099",
        "question": "The plasma glycoprotein afamin has been previously identified as an alternative carrier protein for vitamin E in extravascular fluids such as plasma and cerebrospinal, ovarian follicular, and seminal fluids. \n afamin, a vitamin E-binding protein in human plasma \n the human vitamin E-binding protein afamin \n Afamin is a plasma vitamin E-binding glycoprotein \n The human vitamin E-binding glycoprotein afamin is primarily expressed in the liver and has been associated with prevalent and incident metabolic syndrome \n Do Afamin bind Vitamin E?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622632483a8413c653000081",
        "question": " Maternal systemic and placental inflammatory responses participate in the pathogenesis of hypertensive disorders of pregnancy including preeclampsia, a pregnancy-specific syndrome, although the role of inflammation remains unclear.  \n Our results indicate these proteins are new factors that play important roles in the immunological pathomechanism of preeclampsia. \n Inflammation and oxidative stress at the maternal-fetal interface characterize the placental dysfunction that underlies the pregnancy disorder preeclampsia. \n The abnormal expression of Tim-3 on MDSC might be involved in the pathogenesis of PE, and could be a marker to evaluate the immune function in PE. \n Maternal immune tolerance is important for maintaining pregnancy, and researchers have increasingly focused on the critical roles of cytokines in the pathogenesis of PE in recent years. \n Disruption of well-controlled immune functions leads to infertility, placental inflammation, and numerous pregnancy complications, including preeclampsia (PE). \n Effect of Endogenic and Exogenic Oxidative Stress Triggers on Adverse Pregnancy Outcomes: Preeclampsia, Fetal Growth Restriction, Gestational Diabetes Mellitus and Preterm Birth. \n Disruption of complex immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (PE). \n In addition, it has been demonstrated that immune disturbance may be responsible for some adverse pregnancy outcomes such as preeclampsia (PE), recurrent spontaneous abortion (RSA) and intrauterine growth restriction (IUGR). \n esponse. In previous models of preeclampsia (PE), defective immune function caused by disruption of lymphangiogenesis was shown to be involved in the disease pathophy \n OBJECTIVE: Increased oxidative stress and immune dysfunction are implicated in preeclampsia (PE) and may contribute to the two- to fourfold increase in PE prevalence among women with type 1  \n r, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differentiation of T-helper cell subsets creating a cytotoxic environment in uter \n Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia \n a disrupted immune system might be a predisposing factor or result of placental oxidative stress or excessive inflammation in preeclampsia. Preeclampsia c \n clude insufficient control of inflammation, failure of tolerance toward paternal antigens at the fetal-maternal interface, and subsequent over- or insufficient activation of immune mediators. It is als \n PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of pre \n s review, we focus on the role of excessive systemic inflammation as the result of a dysregulated immune system in the development of preeclampsia. These \n PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of pree \n However, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differentiation of T-helper cell subsets creating a cytotoxic environment in utero. \n In conclusion, a disrupted immune system might be a predisposing factor or result of placental oxidative stress or excessive inflammation in preeclampsia. \n esponse. In previous models of preeclampsia (PE), defective immune function caused by disruption of lymphangiogenesis was shown to be involved in the disease pathoph \n Disruption of this immune balance and/or inadequate placental perfusion is believed to be associated with a lot of pregnancy-related complications, such as recurrent spontaneous abortion, pre-eclampsia, and fetal intrauterine growth restriction. \n Therefore, a delicate immune balance is critical for the maintenance of a successful pregnancy, while disruption of this balance can induce complications such as implantation failure, miscarriage, preterm birth/labor, preeclampsia and fetal growth restriction. \n antigens during pregnancy. Disruption of complex immune regulation mechanisms is associated with adverse pregnancy outcomes, including preeclampsia (P \n ccessful pregnancy. It has been demonstrated that innate immune disturbances may be responsible for some adverse pregnancy outcomes such as preeclamps \n ever, in preeclampsia, the regulation of immune responses is disrupted as a result of aberrant activation of innate immune cells and imbalanced differ \n PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of preeclampsia \n However, immune maladaptation and hemostatic imbalance have been suggested to be responsible for adverse pregnant outcomes, such as preeclampsia (PE), miscarriage, recurrent spontaneous abortion (RSA) and intrauterine growth restriction (IUGR). \n PROBLEM: The purpose of this study is to clarify whether the disruption of immune regulation occurs in early pregnancy before the clinical manifestations of preeclampsia.METHOD OF STUDY: The serum concentrations of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) were determined by using enzyme-linked immunoadsorbent assay (ELISA) in the first trimester of pregnancy in women who had preeclampsia develop after 28 weeks of pregnancy (preeclamptic group) and in women who completed pregnancy uneventfully (control group).RESULTS: Serum concentrations of both IL-2 and TNF-alpha in the first trimester of the preeclamptic group were significantly higher than those of the control group.CONCLUSIONS: That the perturbation of feto-maternal immune regulation may precede the clinical manifestations of preeclampsia, which may be of relevance i \n Preeclampsia can thus be considered a hyperinflammatory state associated with defective regulation of the immune system proposed as a key element in the pathological events of the placental subtype of this disorder. \n Disruption in the Regulation of Immune Responses in the Placental Subtype of Preeclampsia. \n It has been demonstrated that innate immune disturbances may be responsible for some adverse pregnancy outcomes such as preeclampsia (PE); hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome; intrauterine growth restriction (IUGR); and recurrent spontaneous abortion (RSA). \n Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62266c353a8413c65300008a",
        "question": "A Novel Prognostic Prediction Model for Colorectal Cancer Based on Nine Autophagy-Related Long Noncoding RNAs \n A prognostic prediction model of CRC was built based on nine ARlncRNAs (NKILA, LINC00174, AC008760.1, LINC02041, PCAT6, AC156455.1, LINC01503, LINC00957, and CD27-AS1). The 5-year overall survival rate was significantly lower in the high-risk group than in the low-risk group among train set, validation set, and all patients (all p < 0.001). The model had high sensitivity and accuracy in predicting the 1-year overall survival rate (area under the curve = 0.717). The prediction model risk score was an independent predictor of CRC.  \n The new ARlncRNA-based model predicts CRC patient prognosis and provides new research ideas regarding potential mechanisms regulating the biological behavior of CRC. ARlncRNAs may play important roles in personalized cancer treatment. \n Can autophagy related lncRNAs be used for colorectal cancer prognosis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621e9aa13a8413c653000053",
        "question": "Several landmark studies have shown that cohesin mutations perturb the balance between self-renewal and differentiation of hematopoietic stem and progenitor cells (HSPC). Emerging data now begin to uncover the molecular mechanisms that underpin this phenotype. Among these mechanisms is a role for cohesin in the control of inflammatory responses in HSPCs and myeloid cells. Inflammatory signals limit HSPC self-renewal and drive HSPC differentiation. Consistent with this, cohesin mutations promote resistance to inflammatory signals, and may provide a selective advantage for AML progression.  \n Are there roles for cohesin mutations in AML?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622d0aa63a8413c6530000a0",
        "question": "Asf1, a key histone H3-H4 chaperone required for this process, is phosphorylated by Tousled-like kinases (TLKs).  \n The Tousled-like kinases 1 and 2 (TLK1/2) control histone deposition through the ASF1 histone chaperone \n The Tousled-like kinases (TLKs) are involved in chromatin assembly, DNA repair, and transcription. Two TLK genes exist in humans, and their expression is often dysregulated in cancer. TLKs phosphorylate Asf1  \n TLKs interact specifically (and phosphorylate) with the chromatin assembly factor Asf1, a histone H3-H4 chaperone \n TLK1 substrates were identified as the histone H3 and Asf1 (a histone H3/H4 chaperone) \n Is ASF1 phopshorylated by  the Tousled-like kinases?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6237a6e93a8413c6530000b1",
        "question": "S1P-induced FOXO1 and EREG gene expression suggests that the activation of S1P-S1PR axis may cooperate with gonadotropins in modulating follicle development. \n S1P-dependent CREB phosphorylation induced FOXO1 and the EGF-like epiregulin-encoding gene (EREG), confirming the exclusive role of gonadotropins and interleukins in this process, but did not affect steroidogenesis.  \n Does sphingosine-1 phosphoate suppress epiregulin?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62068e67c9dfcb9c09000038",
        "question": "Whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31% after exclusion of common causes. Most diagnoses were non-mitochondrial disorders and included developmental disorders with intellectual disability, epileptic encephalopathies, other metabolic disorders, cardiomyopathies, and leukodystrophies. These would have been missed if a targeted approach was taken, and some have specific treatments. \n Can whole genome sequencing be used for diagnosis of mitochondrial disease?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622662e13a8413c653000085",
        "question": "METTL3-Mediated lncRNA m6A Modification in the Osteogenic Differentiation of Human Adipose-Derived Stem Cells Induced by NEL-Like 1 Protein. \n This study aimed to explore the regulatory mechanism of methyltransferase3 (METTL3) -mediated long non-coding RNA (lncRNA) N6-methyladenosine (m6A) modification in the osteogenic differentiation of human adipose-derived stem cells (hASCs) induced by NEL-like 1 protein (NELL-1). \n This study shows, for the first time, that METTL3 can activate the MAPK signaling pathway by regulating the m6A modification and expression of a lncRNA, thereby enhancing the osteogenic differentiation of hASCs. \n Can METTL3 methylate long noncoding RNAs?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622f6ad13a8413c6530000aa",
        "question": "Helminths and their products can shape immune responses by modulating immune cells, which are dysfunctional in inflammatory diseases such as asthm \n Schistosoma japonicum peptide SJMHE1 suppresses airway inflammation of allergic asthma in mice. \n Schistosoma japonicum infection downregulates house dust mite-induced allergic airway inflammation in mice. \n To our knowledge, it is the first study to reveal the impact of S. japonicum infection on house dust mite induced severe asthma. More in depth investigation is need to elucidate the underlying mechanisms \n Novel T-cell epitopes on Schistosoma japonicum SjP40 protein and their preventive effect on allergic asthma in mice. \n hese results reveal a novel form of immune protective mechanism, which may play an important role in the modulating effect of helminth infection on allergic asthmatic reactions. \n Using a panel of overlapping peptides, we identified T-cell epitopes on SjP40 protein of Schistosoma japonicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. \n Helminths and their products can regulate immune response and offer new strategies to control and alleviate inflammation, including asthma. \n SJMHE1 Peptide from Schistosoma japonicum Inhibits Asthma in Mice by Regulating Th17/Treg Cell Balance via miR-155. \n We previously found that a peptide named as SJMHE1 from Schistosoma japonicum can suppress asthma in mice \n el of overlapping peptides, we identified T-cell epitopes on SjP40 protein of Schistosoma japonicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. These resul \n has been shown that helminth infections including Schistosoma mansoni may modulate atopic diseases including asthma. I \n Schistosoma japonicum infection downregulates house dust mite-induced allergic airway inflammation in mice \n it is the first study to reveal the impact of S. japonicum infection on house dust mite induced severe asthma. More in depth inv \n s study, we investigated the impact of Schistosoma japonicum infection on the allergic airway inflammation induced by repeated intracheal inoculations of house dust mites (HDM), which is a Th17 and neutrophils dominant murine asthma model, mimicking severe asthma. We found \n Schistosoma japonicum infection showed protective effects against allergic airway inflammation (AAI). \n Therefore, we hypothesize that Schistosoma japonicum egg antigens, a type of native antigen, can induce production of CD4(+) CD25(+) T cells with regulatory activity, modulating airway inflammation and inhibiting asthma development. \n Schistosoma japonicum infection modulates the development of allergen-induced airway inflammation in mice. \n It has been shown that helminth infections including Schistosoma mansoni may modulate atopic diseases including asthma. \n Schistosoma japonicum egg antigens stimulate CD4 CD25 T cells and modulate airway inflammation in a murine model of asthma. \n Most previous studies focused on understanding the preventive effect of S. japonicum infection on asthma (infection before allergen sensitization), whereas the protective effects of S. japonicum infection (allergen sensitization before infection) on asthma were rarely investigated. \n In conclusion, our data showed that lung-stage S. japonicum infection could relieve OVA-induced asthma in a mouse model. \n In this study, we investigated the protective effects of S. japonicum infection on AAI using a mouse model of OVA-induced asthma. \n  prior to OVA immunization. These results suggest that both bisexual and male S. japonicum infections may modulate the development of allergic asthma. \n aponicum, which can induce Th1 cytokine and inhibit the production of Th2 cytokines and airway inflammation in a mouse model of allergic asthma. These \n ve found that Schistosoma infection or Schistosoma related products can improve or prevent some immune and inflammatory diseases, such as severe asthm \n Our findings indicated that S. japonicum infection was able to effectively inhibit host's allergic airway inflammation, which may be related to the upregulated Treg cells upon infection. \n These results suggest that both bisexual and male S. japonicum infections may modulate the development of allergic asthma. \n We found that lung-stage S. japonicum infection significantly ameliorated OVA-induced AAI, whereas post-lung-stage infection did not. \n In a murine model of asthma, S. japonicum egg antigens decreased the expression of Th2 cytokines, relieved antigen-induced airway inflammation, and inhibited asthma development. \n We found that S. japonicum infection downregulated airway hyperresponsiveness. \n However, in recent years, studies have found that Schistosoma infection or Schistosoma related products can improve or prevent some immune and inflammatory diseases, such as severe asthma, inflammatory bowel disease, diabetes and so on. \n In areas where schistosomiasis is endemic, a negative correlation is observed between atopy and helminth infection, associated with a low prevalence of asthma. \n Can parasite infections by Schistosoma japonicum prevent or improve asthma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f80d5d882a024a1000003c",
        "question": "Non-coding region variants upstream of MEF2C cause severe developmental disorder through three distinct loss-of-function mechanisms. \n Clinical genetic testing of protein-coding regions identifies a likely causative variant in only around half of developmental disorder (DD) cases. The contribution of regulatory variation in non-coding regions to rare disease, including DD, remains very poorly understood. We screened 9,858 probands from the Deciphering Developmental Disorders (DDD) study for de novo mutations in the 5' untranslated regions (5' UTRs) of genes within which variants have previously been shown to cause DD through a dominant haploinsufficient mechanism. We identified four single-nucleotide variants and two copy-number variants upstream of MEF2C in a total of ten individual probands. We developed multiple bespoke and orthogonal experimental approaches to demonstrate that these variants cause DD through three distinct loss-of-function mechanisms, disrupting transcription, translation, and/or protein function. These non-coding region variants represent 23% of likely diagnoses identified in MEF2C in the DDD cohort, but these would all be missed in standard clinical genetics approaches. Nonetheless, these variants are readily detectable in exome sequence data, with 30.7% of 5' UTR bases across all genes well covered in the DDD dataset. Our analyses show that non-coding variants upstream of genes within which coding variants are known to cause DD are an important cause of severe disease and demonstrate that analyzing 5' UTRs can increase diagnostic yield. We also show how non-coding variants can help inform both the disease-causing mechanism underlying protein-coding variants and dosage tolerance of the gene. \n Do only changes in coding regions of MEF2C cause developmental disorders?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62211c853a8413c65300006d",
        "question": "CircRNAs are a subclass of lncRNAs that have been found to be abundantly present in a wide range of species, including humans. CircRNAs are generally produced by a noncanonical splicing event called backsplicing that is dependent on the canonical splicing machinery, giving rise to circRNAs classified into three main categories: exonic circRNA, circular intronic RNA, and exon-intron circular RNA.  \n Circular RNA (circRNA) is a large class of covalently closed circRNA. \n Human transcriptome contains a large number of circular RNAs (circRNAs) that are mainly produced by back splicing of pre-mRNA. \n Analyses of the other reads revealed two origins for non-canonical circRNAs: (1) Intronic sequences for lariat-derived intronic circRNAs and intron circles, (2) Mono-exonic genes (mostly non-coding) for either a new type of circRNA (including only part of the exon: sub-exonic circRNAs) or, even more rarely, mono-exonic canonical circRNAs. \n Our objective was to characterize non-canonical circRNAs, namely not originating from back splicing and circRNA produced by non-coding genes. \n Recent studies have identified a new class of ncRNAs called circular RNAs (circRNAs), which are produced by back-splicing and fusion of either exons, introns, or both exon-intron into covalently closed loops. \n CircRNA is produced by the reverse splicing of exon, intron or both, forming exon or intron circRNA. \n Circular RNAs (circRNAs) belong to a recently re-discovered species of RNA that emerge during RNA maturation through a process called back-splicing.  \n Exonic circular RNAs (circRNAs) are RNA molecules that are covalently closed by back-splicing via canonical splicing machinery.  \n Human transcriptome contains a large number of circular RNAs (circRNAs) that are mainly produced by back splicing of pre-mRNA.  \n Circular RNAs (circRNAs) are a class of non\u2011coding RNAs formed by covalently closed loops through back\u2011splicing and exon\u2011skipping.  \n Here, we review the emerging understanding that both, circRNAs produced by co- and posttranscriptional head-to-tail \"backsplicing\" of a downstream splice donor to a more upstream splice acceptor, as well as circRNAs generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes. \n Compared to the linear RNA, circRNAs are produced differentially by backsplicing exons or lariat introns from a pre-messenger RNA (mRNA) forming a covalently closed loop structure missing 3' poly-(A) tail or 5' cap, rendering them immune to exonuclease-mediated degradation. \n CircRNAs are a large class of endogenous single-stranded RNA that is different from other linear RNA, which are produced by back-splicing and fusion of either exons, introns, or both exon-intron into covalently closed loops. \n Circular RNAs (circRNAs) derived from back-spliced exons have been widely identified as being co-expressed with their linear counterparts. \n Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620c27e93a8413c653000006",
        "question": " Here we find METTL1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. METTL1 depletion causes decreased abundance of m7G-modified tRNAs and altered cell cycle and inhibits oncogenicity. Conversely, METTL1 overexpression induces oncogenic cell transformation and cancer.  \n Is METTL1 overexpression associated with better patient survival?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f80c37882a024a1000003b",
        "question": "KCNT2 variants resulting in substitutions affecting the Arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt. We report two additional individuals with intellectual disability, dysmorphic features, hypertrichosis, macrocephaly and the same de novo KCNT2 missense variants affecting the Arg190 residue as previously described. Notably, neither patient has epilepsy. Homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of KCNT2 resulting in a constitutively open state. This is the first report of pathogenic variants in KCNT2 causing a developmental phenotype without epilepsy. \n Do mutations in KCNT2 only cause phenotypes with epilepsy?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f593f8882a024a1000000f",
        "question": "Among the main oral manifestations of IBD are cobblestoning of the oral mucosa, labial swellings with vertical fissures, pyostomatitis vegetans, angular cheilitis, perioral erythema, and glossitis.  \n Pyostomatitis Vegetans: A Clue for Diagnosis of Silent Crohn's Disease. \n We present a case of Pyostomatitis vegetans involving gingiva and oral mucosa with no skin lesion which led to the diagnosis of Crohn's disease to emphasize important role of dentists in diagnosis of rare oral lesions and management of patients' systemic disease. \n Moreover, in both CD and UC, there occur several other inflammatory skin conditions such as erythema nodosum, pyoderma gangrenosum, hidradenitis suppurativa, chronic oral aphthous disease, Sweet syndrome, pyostomatitis vegetans, and bowel-associated dermatosis-arthritis syndrome.  \n Diffuse mucosal swelling, cobblestone mucosa, localised mucogingivitis, deep linear ulceration, fibrous tissue tags, polyps, nodules, pyostomatitis vegetans, and aphthous-like ulcers have been described in Crohn's disease.  \n Aphthous stomatitis and pyostomatitis vegetans are among non-specific oral manifestations of IBD. \n Pyostomatitis vegetans (PV) is a rare, chronic mucocutaneous disorder associated with inflammatory bowel disease (IBD). Oral lesions of PV are distinct and present as multiple white or yellow pustules with an erythematous base that coalesce and undergo necrosis to form a typical \"snail tracks\" appearance. Two cases of PV associated with IBD--one with Crohn's disease (CD) and the other with ulcerative colitis (UC) are reported. \n  Oral involvement during IBD includes several types of lesions: the most common are aphthae; uncommon lesions include, among others, pyostomatitis vegetans and granulomatous lesions of CD.  \n Pyostomatitis vegetans (PV) is a rare condition characterized by pustules that affect the oral mucosa. It is a highly specific marker for inflammatory bowel disease and its correct recognition may lead to the diagnosis of ulcerative colitis or Crohn's disease.  \n matitis and pyostomatitis vegetans are among non-specific oral manifestations of IBD. In differe \n on-specific manifestations, such as aphthous stomatitis and angular cheilitis, occur in both diseases, while pyostomatitis vegetans is more pronounced in patients with UC. Non-specific lesio \n ment during IBD includes several types of lesions: the most common are aphthae; uncommon lesions include, among others, pyostomatitis vegetans and granulomatous lesions of CD. Starting wit \n s ulcers, pyostomatitis vegetans, cobblestoning and gingivitis are important oral findings frequently observed in IBD patients. Their p \n e main oral manifestations of IBD are cobblestoning of the oral mucosa, labial swellings with vertical fissures, pyostomatitis vegetans, angular cheilitis, perioral erythema, and glossitis. In this sen \n Pyostomatitis vegetans is frequently associated with chronic inflammatory bowel diseases and can, thus, give a diagnostic hint at an existing ulcerative colitis or Crohn\u0092s disease. \n Oral Crohn's disease and pyostomatitis vegetans. An unusual association. \n [Pyostomatitis vegetans and Crohn's disease. A specific association of 2 diseases]. \n osis of Crohn's disease. Clinical manifestations improved dramatically with prednisone.DISCUSSION: This case of pyostomatitis-pyodermatitis vegetans involved several aspects rarely reported in the literature: a) the cutaneomucosal signs were inaugural; b) the association with Crohn's disease; c) the presence of lesions to the genital mucosa; d) the unusual localization  \n Pyostomatitis vegetans is a specific marker for ulcerative colitis and Crohn's disease. \n The pathogenetic interrelationship between pyostomatitis vegetans and Crohn's disease is discussed. \n Successful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with Crohn's disease. \n Infliximab and methotrexate may be a promising treatment for the rare cases of pyostomatitis vegetans associated with Crohn's disease. \n INTRODUCTION: Pyostomatitis vegetan (PV) is often associated with chronic inflammatory bowel disease (IBD).OBSERVATION: Tw \n Is there an association between pyostomatitis vegetans and Crohn's disease?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217e1ac3a8413c653000031",
        "question": " activated platelets, which carry peripheral serotonin, \n Platelet serotonin response was measured by serotonin augmented platelet aggregation and platelet serotonin receptor density.  \n SERT was studied in the 1970s and 1980s using membrane vesicles isolated from blood platelets. \n platelet-dense granules contain neurotransmitters such as serotonin and gamma-aminobutyric acid. Molecular players controlling granule formation and secretion are \n Platelets transport and store virtually all plasma serotonin in dense granules \n Is serotonin transported by platelets?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f59592882a024a10000010",
        "question": "It seems that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients.  \n The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness. \n Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab. \n Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease \n CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. \n The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness.Sotrovimab is a monoclonal antibody that works directly against the spike protein of SARS-CoV-2 to block its attachment and entry into a human cell. \n In patients with non-severe covid-19, casirivimab-imdevimab probably reduces hospitalisation; bamlanivimab-etesevimab, bamlanivimab, and sotrovimab may reduce hospitalisation. Convalescen \n ms that monoclonal antibodies (e.g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab) are a better choice for treating severe or non-severe COVID-19 patients. Clini \n Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab \n The Food and Drug Administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate COVID-19 in patients at increased risk for progression to severe illness \n Is Sotrovimab effective for COVID-19?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621b5bcc3a8413c65300003d",
        "question": "otoconia matrix protein, otolin-1 \n Otolin-1 is a collagen-like protein expressed in the inner ear of vertebrates.  \n Mammalian Otolin: a multimeric glycoprotein specific to the inner ear that interacts with otoconial matrix protein Otoconin-90 and Cerebellin-1 \n binds to otolin-1 and forming matrix protein architectures \n Is Otolin-1 a matrix protein?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "620aedee3a8413c653000001",
        "question": "AGO2 localizes to cytokinetic protrusions in a p38-dependent manner and is needed for accurate cell division. \n We suggest that AGO2 is part of a regulatory mechanism triggered by cytokinetic stress to generate the appropriate micro-environment for local transcript homeostasis. \n Is AGO2 related to cytokinesis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621b61833a8413c65300003e",
        "question": " Both CD10 and HOXA11 have been implicated in regulation of endometrial homeostasis. \n Combined expression of HOXA11 and CD10 identifies endometriosis versus normal tissue and tumors. \n The combination of HOXA11 and CD10 expression profiles provides a useful tool to identify ectopic endometrial tissue and for distinguishing endometriosis from various types of gynecological malignancies and metastases. \n Downregulation of HOXA11 enhances endometrial cancer malignancy \n Low HOXA11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating PTEN/AKT pathway. \n Endometrial mRNA and protein expression levels of HOXA10 and HOXA11 were significantly lower in patients with AM than in control patients. \n Is the protein HOXA11 associated with endometrial disease?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621ed10f3a8413c653000062",
        "question": "The immunosuppressive effects of CD4+ CD25 high regulatory T cells (Tregs) interfere with antitumor immune responses in cancer patients. \n Alteration of regulatory T cells (Tregs) may contribute to ineffective suppression of proinflammatory cytokines in type 1 diabetes.AIM \n Regulatory T cells (Tregs) suppress excessive immune responses in IRI \n CD4(+)CD25(+) regulatory T cells (Tregs) are negative regulators of the immune system that induce and maintain immune tolerance. \n lar to chronic patients, Treg from patients with PHI inhibited the proliferation of purified tuberculin (PPD) and HIV p24 activated CD4CD25 T cells. CD4 \n  demonstrate that aTregs are necessary for tolerance, DBA/2 skin was transplanted onto C57BL/6-RAG-1-deficient recipients adoptively transferred with purified sorted CD4CD25 T cells; half of the recipients undergo tolerance induction treatment.RE \n It is well established that CD4CD25 regulatory T cells (Tregs) downregulate inflammatory immune responses and help to maintain immune homeostasis. \n In vitro expanded human CD4+CD25+ regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses. \n BACKGROUND: Regulatory T cells (Tregs) are essential in the control of tolerance. \n CD4(+)CD25(+) regulatory T cells (Tregs) are critical for the peripheral immune tolerance. \n T regulatory cells (Tregs) have a role in immunosuppression and control of autoimmunity, and are currently an important topic in the study of immune response to tumor cells. \n CD4+CD25+ regulatory T cells attenuate lipopolysaccharide-induced systemic inflammatory responses and promotes survival in murine Escherichia coli infection. \n OBJECTIVES: CD4CD25 regulatory T cells (Tregs) play a key role in the prevention of various inflammatory and autoimmune disorders by suppressing immune responses. \n CD25(High) CD4+ regulatory T cells (Treg cells) have been described as key players in immune regulation, preventing infection-induced immune pathology and limiting collateral tissue damage caused by vigorous anti-parasite immune response. In t \n ic subset of T cells, currently recognized as FOXP3(+) CD25(+) CD4(+) regulatory T cells (Tregs), are pivotal in suppressing autoimmunity and maintaining immune homeostasis by mediating self-tolerance at the periphery as shown in autoimmune diseases and cancers. A growing body of  \n CD4+CD25+ regulatory T cells (Tregs) are essential negative regulators of immune responses.  \n Accumulating evidence has demonstrated that naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) are critical for maintenance of immunological tolerance and have been shown to be important in regulating the immune responses in many diseases. Curcu \n 4+CD25+ Foxp3+ regulatory T cells (Tregs) are recognized as one of the major regulatory factors in immune tolerance and inflammatory responses. Si \n lly occurring CD4(+)CD25(+) regulatory T cells (Tregs) have a key role in the prevention of various inflammatory and autoimmune disorders by suppressing immune responses. We tested t \n CD4(+)CD25(+) regulatory T cells (Tregs) are considered to play a key role as suppressors of immune mediated reactions. The a \n CD4+ CD25+ T regulatory cells (Tregs) are classified as a subset of T cells whose role is the suppression and regulation of immune responses to self and non-self.  \n CD4(+)CD25(+) regulatory T cells (Tregs) are potent modulators of immune responses. \n CD4+ T cells naturally expressing CD25 molecules (natural T regulatory cells (Tregs)) have a role in maintaining self tolerance and in regulating responses to infectious agents, transplantation Ags, and tumor Ags. \n Naturally occurring CD4(+)CD25(+) regulatory T cells (Tregs) are essential for the active suppression of autoimmunity. \n Amongst these, naturally occurring CD4(+)CD25(+) Treg cells (nTreg) represent a major lymphocyte population engaged in the dominant control of self-reactive T responses and maintaining tolerance in several models of autoimmunity. \n CD4+CD25+ regulatory T cells (Tregs) are essential negative regulators of immune responses. \n Naturally occurring CD4(+)CD25(+)FoxP3(+) regulatory T cells (CD25(+) Tregs) constitute a specialized population of T cells that is essential for the maintenance of peripheral self-tolerance. \n One of the subpopulations of CD4+ T cells that express CD25+ and the transcription factor FOXP3, known as Regulator T cells (TReg), plays an essential role in maintaining tolerance and immune homeostasis preventing autoimmune diseases, minimalize chronic inflammatory diseases by enlisting various immunoregulatory mechanisms. \n Regulatory T cells (Tregs) are CD4(+)CD25(bright)CD62L(high) cells that actively down-regulate immune responses. \n CD4(+)CD25(+) regulatory T cells (Treg) play a central role in the prevention of autoimmunity and in the control of immune responses by down-regulating the function of effector CD4(+) or CD8(+) T cells. \n FoxP3(+)CD25(+)CD4(+) regulatory T cells (Tregs) suppress a variety of normal physiological and pathological immune responses via several pathways, such as inhibitory cytokine secretion, direct cytolysis induction, and antigen-presenting cell functional modulation. \n Regulatory CD4(+) CD25(+) T (Treg) cells with the ability to suppress host immune responses against self- or non-self antigens play important roles in the processes of autoimmunity, transplant rejection, infectious diseases and cancers. \n BACKGROUND: Evidence indicating that CD4+CD25+ regulatory T (Treg) cells play a crucial role in the maintenance of peripheral T cell tolerance to allergens has been  \n Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "5fdb4100a43ad31278000015",
        "question": "BRD4 and Mediator were found to co-occupy thousands of enhancers associated with active genes. \n Master transcription factors and mediator establish super-enhancers at key cell identity genes \n Master transcription factors Oct4, Sox2, and Nanog bind enhancer elements and recruit Mediator to activate much of the gene expression program of pluripotent embryonic stem cells (ESCs). \n These domains, which we call super-enhancers, consist of clusters of enhancers that are densely occupied by the master regulators and Mediator \n BRD4 maintains transcription of core stem cell genes such as OCT4 and PRDM14 by occupying their super-enhancers (SEs), large clusters of regulatory elements, and recruiting to them Mediator and CDK9, the catalytic subunit of the positive transcription elongation factor b (P-TEFb), to allow Pol-II-dependent productive elongation. \n The term 'super-enhancer' has been used to describe groups of putative enhancers in close genomic proximity with unusually high levels of Mediator binding, as measured by chromatin immunoprecipitation and sequencing (ChIP-seq). \n Mediator kinase inhibition further activates super-enhancer-associated genes in AML. \n Furthermore, the binding of SIM2 marks a particular sub-category of enhancers known as super-enhancers. These regions are characterized by typical DNA modifications and Mediator co-occupancy (MED1 and MED12).  \n Many genes determining cell identity are regulated by clusters of Mediator-bound enhancer elements collectively referred to as super-enhancers.  \n A number of studies have recently demonstrated that super-enhancers, which are large cluster of enhancers typically marked by a high level of acetylation of histone H3 lysine 27 and mediator bindings, are frequently associated with genes that control and define cell identity during normal development.  \n Super-enhancers are characterized by high levels of Mediator binding and are major contributors to the expression of their associated genes.  \n Is Mediator present at super enhancers?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62057b35c9dfcb9c0900002d",
        "question": "Atemoya juice significantly inhibited CYP1A2 activity in human liver microsomes, but not the activities of CYP2C9 and CYP3A. \n This suggests that the intake of an excess amount of atemoya juice is necessary to cause a change in the pharmacokinetics of phenacetin when the IC50 values for CYP1A2 inhibition by atemoya and fluvoxamine are taken into account \n Does atemoya juice inhibit the CYP1A2 enzyme?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217dc9d3a8413c65300002d",
        "question": "Neurofilament light chain (NfL) has recently been proposed as a promising biomarker in frontotemporal dementia (FTD).  \n Neurofilament light chain (NfL) is a new, non-disease specific, widely studied biomarker indicative of axonal injury and degeneration \n the neurodegeneration biomarker neurofilament light chain (NfL)  \n bNfL can be used as a potential biomarker to predict disease onset, severity, and progression of genetic ataxia. \n Neurofilament light chain protein (NfL) is a promising biomarker of neurodegeneration. \n Is NfL (neurofilament light chain) a biomarker of neurodegeneration?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621ebec63a8413c65300005d",
        "question": " The overall survival rate of the implants into the sinus cavity was 95.6%, without statistical differences according to the level of penetration. The clinical and radiological complications were 3.4% and 14.8% respectively. The most frequent clinical complication was the epistaxis,  \n implant placement and protrusion of the implant up to 3mm beyond the sinus floor does not alter the stability and outcome of dental implants, one year post-restoration. This could be associated with minor complications ranging from epistaxis to sinusitis, which are manageable. \n Is Epistaxis associated with dental implant placement?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f58a1a882a024a10000009",
        "question": "CONCLUSIONS: Oral daprodustat was noninferior to CERA in achieving and maintaining target hemoglobin levels in Japanese ND patients.  \n BACKGROUND: The Anemia Studies in chronic kidney disease (CKD): Erythropoiesis via a Novel prolyl hydroxylase inhibitor (PHI) Daprodustat-Dialysis (ASCEND-D) trial will test the hypothesis that daprodustat is non-inferior to comparator epoetin alfa or darbepoetin alfa for two co-primary endpoints: haemoglobin efficacy and cardiovascular safety. \n Daprodustat is one of the orally administrated small-molecule HIF-PH inhibitors, leading to an increase in erythropoietin production, which is regulated by HIF. Also, daprodustat is expected to improve iron metabolism. Recently, several clinical trials showed its efficacy and safety in both hemodialysis- and non-hemodialysis- dependent CKD patients.  \n Once-daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in Japanese peritoneal dialysis participants. \n Daprodustat is a hypoxia-inducible factor-prolyl hydroxylase inhibitor for the treatment of anemia of chronic kidney disease.  \n Daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, is being investigated for treatment of anemia in chronic kidney disease. \n Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis. \n ONCLUSIONS: Among patients with CKD and anemia who were not undergoing dialysis, daprodustat was noninferior to darbepoetin alfa with respect to the change in the hemoglobin level from baseline and with respect to cardiovascular outcomes.  \n Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis. \n CONCLUSIONS: Among patients with CKD undergoing dialysis, daprodustat was noninferior to ESAs regarding the change in the hemoglobin level from baseline and cardiovascular outcomes. \n Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of anemia of chronic kidney disease. \n BACKGROUND: Daprodustat (GSK1278863) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor being developed for treatment of anemia associated with chronic kidney disease (CKD). \n Daprodustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed for treating anemia of chronic kidney disease. \n Daprodustat is under development as an emerging new class of agents for the treatment of anemia associated with chronic kidney disease (CKD). \n Conclusion: Daprodustat was efficacious and well tolerated for anemia in both NDD and DD patients in the short term based on current RCTs. \n And daprodustat may become an effective alternative for treatment of anemia with CKD. \n Is Daprodustat effective for anemia?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "621218353a8413c653000013",
        "question": "CD3-engaging bispecific antibodies (bsAbs) and chimeric antigen receptor (CAR) T cells are potent therapeutic approaches for redirecting patient T cells to recognize and kill tumors. Here we describe a fully human bsAb (REGN5458) that binds to B-cell maturation antigen (BCMA) and CD3, and compare its antitumor activities vs those of anti-BCMA CAR T cells to identify differences in efficacy and mechanism of action.  \n Is REGN5458 a single-targeted antibody?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6020a7391cb411341a00007e",
        "question": "Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms.  \n The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab. \n f-label use of dupilumab, reslizumab, mepolizumab, and benralizumab can be effective in CU. Ligel \n Finally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. \n ments aimed at reducing eosinophil accumulation and activation, such as the anti-IL-5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce CSU symptoms. Clearly, a new pi \n ormation on the effects of the off-label use, in CSU, of biologics licensed for the treatment of other diseases, including dupilumab, benralizumab, mepolizumab, reslizumab, and secukinumab. Finally, we discuss \n , B cells, T cells and eosinophils. The treatments that are under clinical trials for CSU are anti-IgE treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec-8, anti-IL-1s such as canakinumab, Bruton kinase (BTK) inhibitors such as GDC-0853 and anti-IL-5s such as benralizumab and mepolizumab.SUMMARY: The ongoing clinical trials on new targets of treatment hold new hopes not only for a better care of the disease but also a better understan \n Is Benralizumab effective for Chronic Spontaneous Urticaria?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217dd013a8413c65300002f",
        "question": "we show that Amot binds Talin and is essential for relaying forces between fibronectin and the cytoskeleton \n Do the proteins Talin and Amot interact?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6220cbf83a8413c653000067",
        "question": " We investigated 2 mRNA-binding proteins - HuR and TIAR showing specificity to AU-Rich Element (ARE) sites in 3'UTR of mRNA. \n Bioinformatics analysis of the human SOD1 mRNA 3' untranslated region (3'UTR) demonstrated the presence of HuD binding adenine-uridine (AU)-rich instability-conferring elements (AREs). \n We found that AU-rich element RNA binding protein 1 (AUF1) directly binds to the Cry1 3'UTR and regulates translation of Cry1 mRNA. \n Adenylate/uridylate-rich elements (AREs) are the most common cis-regulatory elements in the 3'-untranslated region (UTR) of mRNAs, where they fine-tune turnover by mediating mRNA decay. \n HuR binding to AU-rich elements present in the 3' untranslated region of Classical swine fever virus. \n Previous reports indicate that distinct RNA sequence in the BDNF 3'UTRs differentially regulates BDNF production in the brain to accommodate neuronal activity changes, conceivably through differential interactions with undefined trans-acting factors that regulate stability and translation of these BDNF mRNA isoforms. \n The 5' untranslated region (UTR) of CSFV contains the IRES, which is a highly structured element that recruits the translation machinery. \n Although AU-rich elements (AREs) in the 3'UTR of interleukin-6 (IL-6) mRNA dictate mRNA degradation, the role of TTP in the post-transcriptional regulation of IL-6 gene expression is unclear. \n We cloned the full-length cDNA of rabbit RGS4, which contains a long 3'-untranslated region (UTR) with several AU-rich elements (AREs). \n Luciferase reporter assays demonstrate that HuR specifically regulates FOXO1 expression through AU-rich elements (AREs) within the FOXO1 3' UTR. \n Additionally, we demonstrated that RNPC1 could bind to PR mRNA via AU-rich elements (AREs) within PR 3'-untranslated region (3'-UTR) and then enhance PR mRNA stability. \n Here, we find that CXCR4 harbors AU-rich elements (AREs) in the 3'-untranslated region (3'-UTR) that bind and respond to the RNA-binding proteins, tristetraprolin (TTP/ZFP36) and HuR (ELAVL1). \n These proteins bind to adenine uridine-rich element (ARE) in the 3'untranslated region of target messenger RNA and stimulate target degradation. \n t mRNAs. RNA-binding proteins can control mRNA stability by binding to AU- and U-rich elements located in the 3'-untranslated regions (3'-UTRs) of target \n y RNA-binding proteins (RBPs) have been shown to recognize and bind to mRNAs that contains AREs generally present in the 3'UTR of mRNAs. RBPs  \n at AREs in the 3'UTR control TSP-1 mRNA stability and that the RNA binding protein AUF1 participates in this control. These studies suggest t \n mber of the Elav family of RNA-binding proteins, has been implicated in this pathway through its binding to adenine and uridine (AU)-rich stability elements (ARE) located in the 3' untranslated regions (3'-UTRs) of the mRNA. Whereas three  \n Hu proteins are RNA-binding proteins that are implicated in the control of stabilization, nuclear export, and/or translation of specific mRNAs with AU-rich elements (AREs) in the 3'-untranslated region. Th \n Post-transcriptional mRNA regulation by RNA binding proteins (RBPs) associated with AU-rich elements (AREs) present in the 3' untranslated region (3'UTR) of specific mRNAs modulates transcript stability and translation in eukaryotic cells. \n In the 3'-untranslated region, the destabilizing adenine-uridine (AU)-rich elements (AREs) control the expression of several transcripts through interactions with ARE-binding proteins (AUBPs) and RNA degradation machinery. \n The AU/U-rich element-binding protein HuR has been shown to bind to p53 mRNA 3'UTR and enhance translation in response to DNA-damaging UVC radiation. \n The AUF1 (hnRNPD) and HuR (ELAV-like) proteins, potential trans-acting factors for regulated mRNA decay, bind in vitro to A+U-rich elements (AREs) found in the 3' untranslated region (3' UTR) of many labile transcripts. \n NCL binds to the AU-rich element (ARE) in the 3'UTR of target mRNAs, mediates miRNA functions in the nearby target sequences, and regulates mRNA deadenylation. \n We investigated 2 mRNA-binding proteins - HuR and TIAR showing specificity to AU-Rich Element (ARE) sites in 3'UTR of mRNA. \n Secondly, the degradation of some mRNAs related to immune responses has been reported to be regulated by binding of RNA-binding proteins to adenylate uridylate-rich elements (AU-rich elements, AREs) located in the 3'-untranslated region (3'-UTR). \n Here, we review the interplay between six well-known RBPs (TTP, AUF-1, KSRP, HuR, TIA-1, and TIAR) that recognize AU-rich elements (AREs) at the 3' untranslated regions of mRNAs, namely ARE-RBPs. \n Hu proteins have been shown to bind to AU-rich elements (AREs) in the 3'-untranslated region of unstable mRNAs. \n Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6211566a3a8413c653000010",
        "question": "CPX-351 (United States: Vyxeos\u00ae; Europe: Vyxeos\u00ae Liposomal), a dual-drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1:5 molar ratio, is approved by the US FDA and the EMA for the treatment of adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. \n Has CPX-351 been approved by the FDA and the EMA?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6217dc173a8413c65300002b",
        "question": "a multitude of symbiotic bacteria and bacteriophages are decreased in abundance in patients with COVID-19 \n Bacterial viruses (bacteriophages, phages) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease. \n Already without exogenous intervention, a multitude of phage-bacterial interactions occur within the human gut, some of which might play a direct role in disease progression \n We are surrounded by microbes, mostly bacteria and their viruses or phages, on the inside and outside of our bodies.  \n crAssphages are a broad group of diverse bacteriophages in the order Caudovirales that have been found to be highly abundant in the human gastrointestinal tract. Despite their high prevalence, we have an incomplete understanding of how crAssphages shape and respond to ecological and evolutionary dynamics in the gut. \n Do we find bacteriophages in the gut?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "601d6fe11cb411341a000033",
        "question": "In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also under regulatory review in Japan for the treatment of Waldenstr\u00f6m's macroglobulinemia and lymphoplasmacytic lymphoma. Clinical development is underway in the USA, Europe and Japan for autoimmune disorders, chronic lymphocytic leukaemia, B cell lymphoma, Sjogren's syndrome, pemphigus and rheumatoid arthritis. This article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in Japan. \n CONCLUSION: These data indicate favorable efficacy of tirabrutinib in patients with relapsed/refractory PCNSL. \n Tirabrutinib was well tolerated and showed promising efficacy for B-cell NHL/CLL. \n rabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabrutinib is also  \n Here, we provide a comprehensive review of the preclinical and clinical activity of tirabrutinib, a drug approved in Japan for relapsed or refractory primary central nervous system lymphoma and all lines of Waldenstr\u00f6m macroglobulinemia/lymphoplasmacytic lymphoma. \n Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton's tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). \n A 64-year-old patient with recurrent PCNSL enrolled in the phase I/II clinical trial of tirabrutinib, a second-generation BTK inhibitor designed for treating relapsed/refractory PCNSL. \n BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL).M \n  2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. Tirabru \n ine kinase inhibitor tirabrutinib (for relapsed and refractory PCNSL) and high-dose chemotherapy with autologous stem cell transplantation support using thiotepa and busulfan (BuTT) were approved by the Japanese Ministry of Health and Welfare in March 2020 and has recently become available for clinical practice. While these novel \n BACKGROUND: The safety, tolerability, efficacy, and pharmacokinetics of tirabrutinib, a second-generation, highly selective oral Bruton's tyrosine kinase inhibitor were evaluated for relapsed/refractory primary central nervous system lymphoma (PCNSL).METHODS: Patients with relapsed/refractory PCNSL, Karnofsky performance status \u226570, and normal end-organ function received tirabrutinib 320 and 480  \n Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma. \n In March 2020, oral tirabrutinib was approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma. \n Is tirabrutinib effective for lymphoma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6212c25c3a8413c653000019",
        "question": "Together with the frequent simultaneous deletions of KMT2A, ATM and CBL and mutations of ASXL1, SF3B1 and CBL, we show that CADM1 may be important in the physiopathology of the del(11q) MDS, extending its role as tumor-suppressor gene from solid tumors to hematopoietic malignancies. \n The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11. \n Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "625374a8e764a53204000027",
        "question": "Pancreaticobiliary subtype of Periampullary carcinoma (PAC) has a poor prognosis in comparison to the intestinal subtype. \n MUC1, CK20, and CDX2 immunohistochemical markers can sub-classify periampullary carcinomas into pancreaticobiliary, intestinal, and mixed subtypes. \n Pancreaticoduodenectomy (PD) is a complex surgical procedure involving resection of the duodenum, the pancreatic head and uncinate process, and the distal common bile duct. It is most commonly performed for periampullary malignancy but may also be indicated in select cases of chronic pancreatitis or benign periampullary tumors. \n In patients suspected of pancreatic or periampullary cancer, abdominal contrast-enhanced computed tomography (CT) is the standard diagnostic modality. \n The pre-operative neutrophil-to-lymphocyte ratio (NLR), when \u22655 has been associated with reduced survival for patients with various gastrointestinal tract cancers, however, it's prognostic value in patients with periampullary tumour has not been reported to date. \n Comparison Of Biliary Stenting And Surgical Bypass In Palliative Management Of Irresectable Periampullary Carcinoma. \n  Some 20-40% of the periampullary carcinoma is irresectable at the time of diagnosis. Biliary stenting and surgical bypass are commonly used palliative procedure. \n Whereas Periampulary AdenoCarcinoma (PAC) having four anatomic subtypes, pancreatic, Common Bile Duct (CBD), ampullary and duodenum shows relative better prognosis \n DEFINITION: Periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors.METHODS: In the present study, we retrospectively reviewed the medical records of 16 patients with periampullary carcinomas over 10 years.RESULTS: 16 patients, 10 men and 6 women (median age 66.7 years, range 42-80) had a  \n Periampullary carcinomas: a special entity of duodenal tumors. \n Periampullary adenocarcinomas are rare neoplasm that originates from the pancreatic head, the ampulla of vater, the distal bile duct or the duodenum. \n Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62015485c9dfcb9c09000023",
        "question": "Recapitulation and Reversal of Schizophrenia-Related Phenotypes in Setd1a-Deficient Mice. \n SETD1A, a lysine-methyltransferase, is a key schizophrenia susceptibility gene. Mice carrying a heterozygous loss-of-function mutation of the orthologous gene exhibit alterations in axonal branching and cortical synaptic dynamics accompanied by working memory deficits. We show that Setd1a binds both promoters and enhancers with a striking overlap between Setd1a and Mef2 on enhancers. Setd1a targets\u00a0are highly expressed in pyramidal neurons and display a complex pattern of transcriptional up- and downregulations shaped by presumed opposing functions of Setd1a on promoters and Mef2-bound enhancers. Notably, evolutionarily conserved Setd1a targets are associated with neuropsychiatric genetic risk burden. Reinstating Setd1a expression in adulthood rescues cognitive deficits. Finally, we identify LSD1 as a major counteracting demethylase for Setd1a and show that its pharmacological antagonism results in a full rescue of the behavioral and morphological deficits in Setd1a-deficient mice. Our findings advance understanding of how SETD1A mutations predispose to schizophrenia (SCZ) and point to novel therapeutic interventions. \n Do SETD1A mutations predispose to schizophrenia?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f7cca7882a024a1000002b",
        "question": "Sotatercept for the Treatment of Pulmonary Arterial Hypertension. \n CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertension. \n Sotatercept for the Treatment of Pulmonary Arterial Hypertension \n CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background therapy for pulmonary arterial hypertensio \n n hematologic adverse events. One patient in the sotatercept 0.7-mg group died from cardiac arrest.CONCLUSIONS: Treatment with sotatercept resulted in a reduction in pulmonary vascular resistance in patients receiving background t \n Is Sotatercept effective for Pulmonary Arterial Hypertension?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "624f2355e764a5320400000b",
        "question": "The Sino-Nasal-Outcome-Test-22 (SNOT-22) represents the reference questionnaire to assess symptoms, health-related quality-of-life (HRQOL) and treatment-response in patients with chronic rhinosinusitis (CRS).  \n Assessment of health-related quality-of-life in patients with chronic Rhinosinusitis - Validation of the German Sino-Nasal Outcome Test-22 (German-SNOT-22). \n  Patients meeting diagnostic criteria for CRS were prospectively enrolled in a cross-sectional study. Responses from the Sinonasal Outcomes Test-22 (SNOT-22), a measure of patient HRQOL, as well as the Lund-Kennedy and Lund-Mackay scores were recorded at enrollment \n Three groups of 12 participants each were examined: patients with CRS without polyposis (CRS group), patients with symptoms of CRS but radiologically normal sinuses (symptoms-only), and healthy controls. Measurements of nNO were carried out using aspiration method and humming maneuver. All participants completed the Sino-Nasal Outcome Test (SNOT-22). \n PURPOSE: The Sino-Nasal-Outcome-Test-22 (SNOT-22) represents the reference questionnaire to assess symptoms, health-related quality-of-life (HRQOL) and treatment-response in patients with chronic rhinosinusitis (CRS). \n tcomes included scores on the CRS disease severity visual analog scale (VAS), 22-item Sino-Nasal Outcome Test (SNOT-22), 5-dimension EuroQoL (EQ-5D) general health status VAS, and 36-item Short-Form Health Survey (SF-36) for HRQoL and nasal polyp-related healthcare resource use questionnaires.RE \n BACKGROUND: The 22-item Sino-Nasal Outcome Test (SNOT-22) is a commonly utilized outcome measure for chronic rhinosinus \n BACKGROUND: The 22-item sino-nasal outcome test (SNOT-22) is a widely used and powerful patient-reported outcomes measure for chronic rhinosinus \n BACKGROUND: Prior study demonstrated that baseline 22-item Sino-Nasal Outcome Test (SNOT-22) aggregate scores accurately predict selection of surgical intervention in patients with chronic rhinosinus \n OBJECTIVES/HYPOTHESIS: Sinonasal Outcomes Test-22 (SNOT-22) is used widely as a patient-reported sinonasal quality-of-life (QOL) instrument for endoscopic endonasa \n Is sino-nasal outcome test-22 reliable for guiding chronic rhinosinusitis patients for endoscopic sinus surgery \n The Sino-Nasal Outcome Test-22 as a tool to identify chronic rhinosinusitis in adults with cystic fibrosis \n rden. Our objective was to investigate the utility of the 22-item Sino-Nasal Outcome Test (SNOT-22) as a tool to identify CRS in adults wit \n OBJECTIVES/HYPOTHESIS: The 22-item Sinonasal Outcome Test (SNOT-22) is a validated chronic rhinosinusitis health-related quality-of-life outcome (HRQoL) measure; however, SNOT-22 domains have not been validated specifically for chronic rhinosinusitis with nas \n OBJECTIVE: The SNOT-22 (22-item Sinonasal Outcome Test) is a high-quality outcome measure that assesses chronic rhinosinusitis-specific quality of lif \n BACKGROUND: The 22-item sino-nasal outcome test (SNOT-22) is a widely used and powerful patient-reported outcomes measure for chronic rhinosinusitis (CRS \n OBJECTIVES/HYPOTHESIS: The 22-item Sinonasal Outcome Test (SNOT-22) is a validated chronic rhinosinusitis health-related quality-of-life outcome (HRQoL) measure; however, SNOT-22 domains have not been validated specifically for chronic rhinosinusitis with nasal polyps (CRSwNP \n BACKGROUND: The 22-item Sino-Nasal Outcome Test (SNOT-22) is a commonly utilized outcome measure for chronic rhinosinusitis (CRS \n OBJECTIVES/HYPOTHESIS: The 22-item Sinonasal Outcome Test (SNOT-22) is a validated chronic rhinosinusitis health-related quality-of-life outcome (HRQoL) measure; however, SNOT-22 domains have not been validated specifically for chronic rhinosinusitis with nasal polyps (CRSwNP).STUDY DESIGN: Validation of SNOT-22 domain structure, using data from 3 randomized, placebo-controlled, double-blinded, multicenter clinical trials of dupilumab in adults with moderate-to-severe CRSwNP.METHODS: Preliminary dimensional structure was derived by exploratory factor analyses of SNOT-22 data from a phase 2 trial (NCT01920 \n OBJECTIVES: We set out to determine the psychometric validation of a disease-specific health related quality of life instrument for use in chronic rhinosinusitis, the 22 item Sinonasal Outcome Test (SNOT-22), a modification of a pre-existing instrument, the SNOT-20.DESIGN, SETTING AND PARTICIPANTS: The National Comparative Audit of Surgery for Nasal Polyposis and Chronic Rhinosinusitis was a prospective cohort study collecting data on 3128 adult patients undergoing sinonasal sur \n OBJECTIVE: The SNOT-22 (22-item Sinonasal Outcome Test) is a high-quality outcome measure that assesses chronic rhinosinusitis-specific quali \n act of CRS. We sought to determine if 22-item Sino-Nasal Outcome Test (SNOT-22) score is predictive of patient-perceived CRS symptom control.METHODS: Prospective cross-sectional study of 2 \n The Sinonasal Outcome Test (SNOT-22) Is a Poor Diagnostic Tool for Chronic Rhinosinusitis. \n The 22-item Sino-Nasal Outcome Test accurately reflects patient-reported control of chronic rhinosinusitis symptomatology. \n Development of Sinonasal Outcome Test (SNOT-22) Domains in Chronic Rhinosinusitis With Nasal Polyps. \n cture with strong Cronbach's alpha values (all >0.80). Moderate-to-high correlations were observed between change in SNOT-22 domain scores and other study patient-reported outcome measures, along with large effect-size estimates (\u22650.7), demonstrating re \n Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "626aa563e764a53204000036",
        "question": " In this study, we investigated the effect of small interfering RNA (siRNA) of connective tissue growth factor (CTGF) by pRetro-Super (PRS) retrovirus vector on the expression of CTGF and related extracellular matrix molecules in human renal proximal tubular cells (HKCs) induced by high glucose, to provide help for renal tubulointerstitial fibrosis therapy. \n Is pRETRO-SUPER an adenoviral vector?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6201a85cc9dfcb9c0900002a",
        "question": "Independence of chromatin conformation and gene regulation during Drosophila dorsoventral patterning. \n Here, using the dorsoventral patterning of the Drosophila melanogaster embryo as a model system, we provide evidence for the independence of chromatin organization and dorsoventral gene expression. We define tissue-specific enhancers and link them to expression patterns using single-cell RNA-seq. Surprisingly, despite tissue-specific chromatin states and gene expression, chromatin organization is largely maintained across tissues. Our results indicate that tissue-specific chromatin conformation is not necessary for tissue-specific gene expression but rather acts as a scaffold facilitating gene expression when enhancers become active. \n Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61faa1fcc9dfcb9c0900000a",
        "question": "Relevance: Among patients who underwent tumor resection for first or second recurrence of glioblastoma or anaplastic astrocytoma, administration of Toca 511 and Toca FC, compared with SOC, did not improve overall survival or other efficacy end points. \n The median OS was 11.10 months for the Toca 511/FC group and 12.22 months for the control group (hazard ratio, 1.06; 95% CI 0.83, 1.35; P\u2009=\u2009.62). The secondary end points did not demonstrate statistically significant differences.  \n Expert opinion: These early studies provide very encouraging results for Toca 511 and Toca FC in rHGG. This therapy had a response rate of 11.3% and a mOS of 11.9\u00a0months in 56 patients, an improvement compared to historical controls.  \n Findings from a phase I study suggest that delivering high concentrations of the chemotherapy 5-FU directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or Toca 511, may benefit patients with recurrent high-grade glioma. \n Overall survival for recurrent high-grade glioma was 13.6 months (95% confidence interval, 10.8 to 20.0) and was statistically improved relative to an external control (hazard ratio, 0.45; P = 0.003). \n Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f93e68882a024a1000004d",
        "question": "RESULTS: Six participants were enrolled. All had adverse events, mostly behavioral. Two completed the trial and the other four withdrew due to adverse events. All participants reported resolution of these events after discontinuation of the drug. The trial was halted due to the large number of adverse events.DISCUSSION: The use of perampanel in this study of ALS was limited by its poor tolerability \n CONCLUSIONS: Perampanel was associated with a significant decline in ALSFRS-R score and was linked to worsening of the bulbar subscore in the 8\u00a0mg group. \n DISCUSSION: The use of perampanel in this study of ALS was limited by its poor tolerabilit \n Should perampanel be used for amyotrophic lateral sclerosis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "624c88a1e764a53204000002",
        "question": "Special AT-rich sequence binding protein-1 (SATB1) is localized to the nucleus and remodels chromatin structure in T cells \n chromatin organizers SATB2 and SATB1  \n transcription factor complexes. These MYB complexes assemble aberrantly with LYL1, E2A, C/EBP family members, LMO2, and SATB1.  \n Staining for the transcription factors Foxp2, Satb1 and Satb2 labeled most ganglion cells in the avian ganglion cell layer. \n Is Satb1 a transcription factor?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "6228b3553a8413c65300008b",
        "question": "n this review, we summarized the function of circRNAs and indicated their roles in the pathogenesis of DR, which may provide new therapeutic targets for clinical treatment. \n This study aimed to determine whether circular RNAs (circRNAs) in whole blood could be served as novel non-invasive biomarkers for proliferative diabetic retinopathy (PDR).M \n Discovery and validation of hsa_circ_0001953 as a potential biomarker for proliferative diabetic retinopathy in human blood. \n Circular RNA hsa_circ_0000034 (circ_0000034) was reported to be upregulated in RB tissues. \n We recently identified a circular RNA transcript (circGRM4) that is significantly upregulated in the eye of cystathionine \u03b2-synthase-deficient mice. \n Circular and long non-coding RNAs and their role in ophthalmologic diseases. \n In this review, we summarize current knowledge about gene expression regulators - long non-coding and circular RNA molecules in eye diseases. \n fied a circular RNA transcript (circGRM4) that is significantly upregulated in the eye of cystathionine \u03b2-synthase-deficient mice. We also discovered \n NAs (circRNAs) are dominant players regulating their parental genes' expression dynamics, their importance in ocular biology has not been appreciated. Progress in gene-cent \n Circular RNA Expression Profiling Identifies Glaucoma-Related Circular RNAs in Various Chronic Ocular Hypertension Rat Models \n Circular RNAs profiling in the cystathionine-\u03b2-synthase mutant mouse reveals novel gene targets for hyperhomocysteinemia induced ocular disorders \n Circular and long non-coding RNAs and their role in ophthalmologic diseases \n Comprehensive circular RNA profiling of proliferative vitreoretinopathy and its clinical significance \n  these findings, we completed the first in-depth study of rat retinal circular RNA expression profiling to identify probable biomarkers for the diagnosis of glaucoma. Two ocu \n Circular RNAs profiling in the cystathionine-\u03b2-synthase mutant mouse reveals novel gene targets for hyperhomocysteinemia induced ocular disorders. \n Although, increasing evidence suggests that circRNAs may also contribute in different ocular diseases, the outline of circRNAs in ocular diseases remains obscure \n In this review, we summarize current knowledge about gene expression regulators - long non-coding and circular RNA molecules in eye diseases \n Recent studies recognized the vital roles that circRNAs played in the pathogenesis of various eye diseases, highlighting circRNAs as promising biomarkers for diagnosis and assessment of progression and prognosis \n Partly because their circularity makes them resistant to degradation, they hold great promise as unique biomarkers for ocular and central nervous system (CNS) disorders \n In this review we consider the current state of knowledge regarding the potential role and underlying mechanism of circRNAs in ocular diseases including pterygium, age-related cataract, glaucoma, diabetic retinopathy, retinoblastoma, retinal vascular dysfunction and hyperhomocysteinemia induced ocular diseases, emphasizing that circRNAs could be promising biomarkers for the diagnosis and prognosis evaluation. \n Recent studies recognized the vital roles that circRNAs played in the pathogenesis of various eye diseases, highlighting circRNAs as promising biomarkers for diagnosis and assessment of progression and prognosis. \n Although, increasing evidence suggests that circRNAs may also contribute in different ocular diseases, the outline of circRNAs in ocular diseases remains obscure. \n Circular RNAs: Novel Promising Biomarkers in Ocular Diseases. \n This review summarizes our current perception of the properties, biogenesis, and functions of circRNAs and the development of circRNA researches related to ophthalmologic diseases, including diabetic retinopathy, age-related macular degeneration, retinopathy of prematurity, glaucoma, corneal neovascularization, cataract, pterygium, proliferative vitreoretinopathy, retinoblastoma, and ocular melanoma. \n CircRNA Is a Rising Star in Researches of Ocular Diseases. \n Interventions targeting circRNAs provide insights for developing novel treatments for these ocular diseases. \n Future circRNAs-targeted intervention may become a novel therapeutic tool for the treatment of ocular diseases. \n Findings also revealed several microRNAs that are specific to each circRNA suggesting their roles in HHcy induced ocular disorders. \n Therefore, circRNAs may serve as potential regulators of corneal LG. \n Expression profiling of circular RNAs in glaucoma, which is a form of optic neuropathy, has not been performed to date. \n Although circular RNAs (circRNAs) are dominant players regulating their parental genes' expression dynamics, their importance in ocular biology has not been appreciated. \n Progress in gene-centered analytics via improved microarray and bioinformatics are enabling dissection of genomic pathways however there is an acute under-representation of circular RNAs in ocular disorders. \n Circular RNAs constitute an inherent gene regulatory axis in the mammalian eye and brain 1. \n Together with the target microRNAs underlying the top differentially expressed circular RNAs, a new target of hsa_circ_0023826 and its host gene TENM4 were identified and further verified in the aqueous humor of glaucoma patients, indicating a promising biomarker for the disease. \n Recent studies suggest that they are differentially expressed both in healthy ocular tissues as well as in eye pathologies, such as neovascularization, proliferative vitreoretinopathy, glaucoma, cataract, ocular malignancy or even strabismus. \n Are circular RNAs implicated in diseases of the eye?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "626aaaa8e764a5320400003a",
        "question": "Epigenetic alterations (epimutations) could thus contribute to heritable variation within populations and be subject to evolutionary processes such as natural selection and drift.  \n Can epigenetic modifications be heritable?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f7d2a5882a024a10000032",
        "question": "In particular, depletion (Obinutuzumab, anti-CD20 monoclonal antibody) or neutralization (Belimumab, anti-\"B-cell activating factor\" monoclonal antibody) of B lymphocytes, and the use of a calcineurin inhibitor with a low profile of renal and systemic toxicity (Voclosporin) demonstrated an improvement in renal response in addition to standard therapy. \n In this viewpoint, we discuss the pros and cons of voclosporin and belimumab as add-on agents to standard therapy, the first drugs to be licenced for lupus nephritis after recent successful randomised phase III clinical trials.  \n Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). \n A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. \n Thus, our data suggest that the addition of belimumab to standard therapy could attenuate the risk of lupus nephritis flare and eGFR decline in a broad spectrum of patients with lupus nephritis. \n Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review. \n JECTIVE: To describe a patient whose active SLE (including lupus nephritis) was managed with the use of belimumab throughout pregnancy.ME \n Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis. \n With vast implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with SLE, specifically lupus nephritis. \n CENT FINDINGS: Recently, the Belimumab in Subjects with Systemic Lupus Erythematosus - Lupus Nephritis trial tested belimumab, an inhibitor of B-cell activating factor, as an add-on therapy to steroids and either mycophenolate mofetil (MMF) or cyclophosphamide when given IV monthly over a period of 104 weeks at an effect size of 11% for a Primary Efficacy Renal Response. T \n Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis. L \n st implications through a novel mechanism, belimumab offers a new standard of treatment for physicians in the complications associated with SLE, specifically lupus nephritis. By targ \n Efficacy of novel monoclonal antibody belimumab in the treatment of lupus nephritis \n ic agents, rituximab may be used for refractory lupus nephritis patients in combination with another DMARD, and belimumab was recently approved by the US Food and Drug Administration for cSLE treatment in children aged > 5 years. New therapies targeting CD20, suc \n s end, there is limited post-hoc randomized evidence to suggest beneficial effect of belimumab, administered on top of standard-of-care, during maintenance therapy in lupus nephritis. Type I  \n e of recently approved belimumab in lupus nephritis eagerly awaits further documentation. Aggre \n Recently introduced into the market, belimumab (Benlysta) is a monoclonal antibody that has potential clinically efficacious applications for the treatment of lupus nephritis \n Belimumab may decrease flare rate and allow glucocorticoid withdrawal in lupus nephritis (including dialysis and transplanted patient). \n Is Belimumab used for lupus nephritis?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62507ca3e764a5320400000f",
        "question": "Our study confirmed that SOX10 is an oncogene and activate Notch signaling pathway, which suggests the potential treatment for melanoma patients by target SOX10/Notch axis. \n The most commonly used melanocytic markers include S100, Melan-A, HMB45 and SOX10 \n melanocytic markers melan-A and SOX10  \n Is SOX10 expressed in melanoma cells?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f939a5882a024a1000004a",
        "question": "BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated with sorafenib. \n INTERPRETATION: Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafenib. \n At a median follow-up of 18\u00b71 months (IQR 14\u00b71-23\u00b71), median overall survival was 8\u00b74 months (95% CI 6\u00b78-10\u00b70) in the tivantinib group and 9\u00b71 months (7\u00b73-10\u00b74) in the placebo group (hazard ratio 0\u00b797; 95% CI 0\u00b775-1\u00b725; p=0\u00b781). \n In Phase I and II studies, tivantinib (ARQ 197), an oral inhibitor of MET, demonstrated promising antitumor activity in patients with HCC, both as monotherapy and in combination with sorafenib. A randomized Phase II trial in second-line HCC showed improved overall survival (hazard ratio: 0.38; p = 0.01) in patients with MET-high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.  \n This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma.  \n Median progression-free survival was 2.8 (95% confidence interval: 2.7-2.9) and 2.3 (1.5-2.8) mo in the tivantinib and placebo groups, respectively (hazard ratio\u00a0=\u00a00.74, 95% confidence interval: 0.52-1.04, P\u00a0=\u00a0.082). Median overall survival was 10.3 (95% confidence interval: 8.1-11.6) and 8.5 (6.2-11.4) mo in the tivantinib and placebo group, respectively (hazard ratio\u00a0=\u00a00.82, 95% confidence interval: 0.58-1.15).  \n This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma. \n This study did not confirm the significant efficacy of tivantinib as a second-line treatment for Japanese patients with MET-high hepatocellular carcinoma \n INTERPRETATION: Tivantinib did not improve overall survival compared with placebo in patients with MET-high advanced hepatocellular carcinoma previously treated with sorafeni \n BACKGROUND: Tivantinib (ARQ 197), a selective, oral MET inhibitor, improved overall survival and progression-free survival compared with placebo in a randomised phase 2 study in patients with high MET expression (MET-high) hepatocellular carcinoma previously treated wit \n ostic factor in HCC after sorafenib failure. Tivantinib demonstrated a nearly doubling of progression free and overall survival in the MET high group compared to placebo in a Phase II study in patient \n Is tivantinib effective for MET-high hepatocellular carcinoma?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6250a545e764a53204000012",
        "question": "The 6-question EuroQol 5-Dimension Health Assessment (EQ-5D) is a widely used, simple instrument that monitors general health-related quality of life (HRQoL) in chronic disease.  \n OBJECTIVE: The 6-question EuroQol 5-Dimension Health Assessment (EQ-5D) is a widely used, simple instrument that monitors general health-related quality of life (HRQoL) in chronic disease. \n OBJECTIVE: The 6-question EuroQol 5-Dimension Health Assessment (EQ-5D) is a widely used, simple instrument that monitors general health-related quality of life (HRQoL) in chronic d \n OBJECTIVE: The 6-question EuroQol 5-Dimension Health Assessment (EQ-5D) is a widely used, simple instrument that monitors general health-related quality of life (HRQoL) in chron \n Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f608d4882a024a10000023",
        "question": "Sacituzumab Govitecan (also known by the brand name TRODELVY\u00ae) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short.  \n Sacituzumab govitecan (sacituzumab govitecan-hziy; Trodelvy\u2122) is a Trop-2-directed antibody conjugated to a topoisomerase I inhibitor (SN-38) that is being developed by Immunomedics for the treatment of solid tumours, including breast cancer. \n Results from a phase I/II trial suggest that an antibody-drug conjugate, sacituzumab govitecan, is active against refractory, metastatic triple-negative breast cancer. A \n INTRODUCTION: Sacituzumab govitecan-hziy, approved in 2020 for treatment of metastatic triple-negative breast cancer, provides a new option for a population with a historically poor prognosis with standard  \n Sacituzumab govitecan (SG), the first antibody-drug conjugate (ADC) approved for triple-negative breast cancer, incorporates the anti-TROP2 antibody hRS7 conjugated to a topoisomerase-1 (TOP1) inhibitor payload. We so \n Sacituzumab govitecan was initially approved in April 2020 under accelerated approval for the treatment of patients with metastatic triple-negative breast cancer who received at least two prior therapies for metastatic disease \n The ASCENT trial reports impressive results with a median overall survival (OS) increased from 6.7 months to 12.1 months with sacituzumab govitecan over single-agent chemotherapy, in metastatic triple negative breast cancer (TNBC) patients in second and subsequent line of therapy. We  \n A phase II study indicates that sacituzumab govitecan (IMMU-132), a Trop-2-specific antibody linked to the irinotecan metabolite SN-38, prolongs the progression-free survival of patients with advanced triple-negative breast cancer. I \n agents, sacituzumab govitecan, has been recently granted an accelerated approval for therapy of metastatic triple-negative breast cancer. In this artic \n l 2020, sacituzumab govitecan received accelerated approval in the USA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Sacituzu \n Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer: Clinical Overview and Management of Potential Toxicities. \n ood and Drug Administration) recently approved the use of a Trop2-targeting ADC (antibody-drug conjugate), Sacituzumab Govitecan (IMMU-132), for metastatic, triple-negative breast cancer with at least two prior therapies. Here, we review \n sive disease. Sacituzumab govitecan represents an important advance in the treatment of mTNBC because of its efficacy an \n Sacituzumab govitecan (SG) is a novel antibody-drug conjugate (ADC) that has shown promising efficacy in mTNBC \n The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer. \n In a basket design phase I/II study, sacituzumab govitecan demonstrated promising single-agent therapeutic activity in multiple cancer cohorts, leading to accelerated approval by the U.S. Food and Drug Administration of sacituzumab govitecan-hziy (TRODELVY) for the treatment of patients with metastatic triple-negative breast cancer who had received at least two prior therapies in the metastatic setting. \n Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. \n Expert opinion: Sacituzumab govitecan has promising anti-cancer activity in patients with metastatic TNBC previously treated with at least two prior lines of systemic therapy based on a single arm Phase I/II clinical trial. \n Sacituzumab govitecan has shown promise in cancers outside of TNBC, such as urothelial and lung and is being evaluated in HR-positive breast cancers. \n  prognosis. Sacituzumab govitecan is an antibody-drug conjugate composed of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2), which is expressed in the majority of breast cancers, coupled to SN-38 (topoisomerase I inhibitor) through a proprietary hydrolyzable linker.METHODS: In this randomized, phase 3 trial, we evaluated sacituzumab govitecan as compared with single-agent chemotherapy of the physician's choice (eribulin, vinorelbine, capecitabine, or gemcitabine) in patients with relapsed or refractory metastatic triple-ne \n Expert opinion Sacituzumab govitecan has promising survival benefits in patients with previously treated mTNBC based on data from the ASCENT trial. \n Conclusion Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC. \n Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. \n Sacituzumab Govitecan (also known by the brand name TRODELVY\u00ae) is a new and available treatment for metastatic triple-negative breast cancer, or mTNBC for short. \n Is sacituzumab govitecan effective for breast cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "622905043a8413c65300008e",
        "question": "Acute necrotizing encephalopathy (ANE) is a recently identified, uncommon encephalopathy affecting children. ANE is characterized by a preceding viral illness followed by seizures and rapid progressive neurologic deterioration.  \n Acute necrotizing encephalopathy (ANE) is a specific type of encephalopathy usually followed by febrile infection \n ANE usually occurs in children under 4 years old after influenza infection \n Acute necrotizing encephalopathy of childhood (ANEC) is a disease, characterized by a respiratory or gastrointestinal infection, accompanied with fever, rapid alteration of consciousness, and seizures. \n Acute necrotizing encephalopathy (ANE) is a rare but distinctive type of acute encephalopathy with global distribution. Occurrence of ANE is usually preceded by a virus-associated febrile illness and ensued by rapid deterioration. \n Acute necrotizing encephalopathy (ANE) typically affects young, healthy children who develop rapid-onset severe encephalopathy triggered by viral infections. \n Recurrent acute necrotizing encephalopathy following influenza A in a genetically predisposed family. \n Background: Among the influenza-associated encephalopathies, acute necrotizing encephalopathy (ANE) has a particularly poor prognosis. \n Since it was first recognized, neurological complications including acute necrotizing encephalopathy (ANE) have been globally documented in association with this viral infection. \n Background: Acute necrotizing encephalopathy (ANE) is a rapidly progressive encephalopathy seen commonly in children triggered by various prodromal viral infections, most common being influenza virus and Human herpe \n Background: Acute necrotizing encephalopathy (ANE), known as influenza-associated encephalitis, typically affects \n Acute necrotizing encephalopathy (ANE) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems.  \n Acute necrotizing encephalopathy (ANE) typically affects young, healthy children who develop rapid-onset severe encephalopathy triggered by viral infections \n Background: Acute necrotizing encephalopathy (ANE) is a rapidly progressive encephalopathy seen commonly in children triggered by various prodromal viral infections, most common being influenza virus and Human herpes virus- \n Acute necrotizing encephalopathy (ANE) presents in children after common viral infections \n Acute necrotizing encephalopathy of childhood (ANEC) is a disease characterized by respiratory or gastrointestinal infection and high fever accompanying with rapid alteration of consciousness and seizures \n Background: Acute necrotizing encephalopathy (ANE) is a rapidly progressive encephalopathy seen commonly in children triggered by various prodromal viral infections, most common being influenza virus and Human herpes virus-6.Objective: We report two rare cases of ANE preceded by Chikungunya infection.Cases: A 13-year old girl presented with a three-day history of headache, fever, se \n Acute necrotizing encephalopathy (ANE) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems. \n Acute necrotizing encephalopathy (ANE) presents in children after common viral infections. \n Acute necrotizing encephalopathy of childhood associated with influenza type B virus infection in a 3-year-old girl. \n We report a 12-year-old girl infected with influenza A H1N1 whose clinical course was complicated by rapid progressive neurologic deterioration and striking CT and MRI findings consistent with acute necrotizing encephalopathy (ANE). \n We report a 3-year-old previously healthy girl presenting with acute necrotizing encephalopathy of childhood associated with influenza type B virus infection, which resulted in severe neurologic sequelae. \n Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "6251465ae764a53204000017",
        "question": " the transmembrane lipoprotein phospholemman (FXYD1) \n Phospholemman (FXYD1) is a single-transmembrane protein regulator of Na,K-ATPase, expressed strongly in heart, skeletal muscle, and brain and phosphorylated by protein kinases A and C at Ser-68 and Ser-63, respectively. \n We previously identified FXYD1 (encoding phospholemman; a protein containing the motif phenylalanine-X-tyrosine-aspartate), a gene encoding a transmembrane modulator of the Na, K-ATPase (NKA) enzyme, \n Is Phospholemman a membrane protein?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f93c38882a024a1000004b",
        "question": "Adjusted least-squares mean changes in total UPDRS score in the antiparkinson medication ON state over 36 months for isradipine and placebo recipients were 2.99 (95% CI, 0.95 to 5.03) points versus 3.26 (CI, 1.25 to 5.26) points, respectively, with a treatment effect of -0.27 (CI, -3.02 to 2.48) point (P\u00a0= 0.85). \n Conclusion: Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD. \n ONS: These results are consistent with the recent secondary analysis of the STEADY-PD III clinical trial-suggesting that clinically attainable brain exposure to isradipine may slow early-stage PD progression. \u00a9 2021  \n These findings suggest that greater exposure to isradipine might slow disease progression. \n erm treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD.Primary Funding So \n BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end of t \n RESULTS: Isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy-adjusted Unified Parkinson's Disease Rating Scale parts I-III score over 36\u00a0months (Spearman rank correlation coefficient, rs :  \n  These findings suggest that greater exposure to isradipine might slow disease progressio \n Conclusion: Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage P \n However, in a recently completed phase 3 clinical trial, the dihydropyridine (DHP) LTCC inhibitor isradipine failed to slow disease progression in early PD patients, questioning the feasibility of DHPs for PD therapy. \n BACKGROUND: Recent examination of the STEADY-PD III isradipine clinical trial data concluded that early-stage Parkinson's disease (PD) participants who had longer exposure to isradipine had a significant delay in their need for symptomatic medication, as well as a lower medication burden at the end o \n Can Isradipine slow progression of Early Parkinson Disease?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "625144c9e764a53204000016",
        "question": "sNfL levels during the first demyelinating event of MS are associated with greater impairment of BBB integrity, immune cell extravasation, and brain lesion activity on MRI. \n Neurofilament light chain (NfL) has recently been proposed as a promising biomarker in frontotemporal dementia (FTD). We investigated the correlation of both cerebrospinal fluid (CSF) and serum NfL with detailed neuropsychological data and cognitive decline in a cohort of sporadic and familial FTD. \n Neurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with Alzheimer's dementia, and psychiatric disorders.  \n  Serum neurofilament light chain (sNfL) is a marker of neuroaxonal injury. \n sNfL is associated with ongoing neuroinflammation and predictive of future neurodegeneration in early MS. \n Neurofilament light chain (NfL) is a relatively new biomarker for MS diagnosis and follow up.  \n Is neurofilament light marker for disease?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "62532d42e764a53204000022",
        "question": "While traditional resistance exercises have been widely used to promote muscle strength and hypertrophy in the elderly,  \n  These findings suggest that in young untrained men, progressing from a training frequency of once per week to a training frequency of 5 times per week with equated volume produces similar gains in LBM and muscle strength as a constant training frequency of once per week, over an 8-week training period. \n Resistance training is one of the effective methods to overcome a decline in muscle mass, \n Therefore, in RT prescription for elbow flexors hypertrophy, single-joint exercises such as BC should be emphasized \n Our studies establish that resistance training in older adults with type 2 diabetes results in muscle fiber hypertrophy, despite a greater accumulation of inflammatory cytokine transcripts in muscle. \n Resistance training results in muscle hypertrophy and improves glycemic control in patients with type 2 diabetes. \n Resistance training (RT) is a popular method of conditioning to enhance sport performance as well as an effective form of exercise to attenuate the age-mediated decline in muscle strength and mass. \n Enzyme activities, reflecting oxidative potential; decrease during long-term heavy resistance training, resulting in muscle hypertrophy. \n Optimal adaptations to resistance training (muscle hypertrophy and strength increases) also seem to occur in the late afternoon, which is interesting, since cortisol and, particularly, testosterone (T) concentrations are higher in the morning. \n Heavy resistance training is associated with increased body weight, lean body mass, and muscle cross-sectional area. \n The implications for this are (a) athletes are advised to coincide training times with performance times, and (b) individuals may experience greater hypertrophy and strength gains when resistance training protocols are designed dependent on individual T response. \n Therefore, the combination of resistance training and overexpression of IGF-I induced greater hypertrophy than either treatment alone. \n The intake of protein after resistance training increases plasma amino acids, which results in the activation of signaling molecules leading to increased muscle protein synthesis (MPS) and muscle hypertrophy. \n The rate and amount of muscle hypertrophy associated with resistance training is influenced by a wide array of variables including the training program, plus training experience, gender, genetic predisposition, and nutritional status of the individual. \n Resistance training is commonly prescribed to enhance strength/power qualities and is achieved via improved neuromuscular recruitment, fiber type transition, and/ or skeletal muscle hypertrophy. \n The mechanisms responsible for the changes in basal post-absorptive protein turnover and its impact on muscle hypertrophy following resistance exercise training are unknown. \n It has been proposed that protein supplementation during resistance exercise training enhances muscle hypertrophy. \n BACKGROUND: Effects of resistance training on muscle strength and hypertrophy are well established in adults and younger elderly. \n Chronic resistance training induces increases in muscle fibre cross-sectional area (CSA), otherwise known as hypertrophy.  \n Resistance training of healthy young men typically results in muscle hypertrophy and a shift in vastus lateralis composition away from type IIx fibers to an increase in IIa fiber content \n In resistance training, it has been empirically accepted that muscle hypertrophy is developed by low intensity and high volume training, while muscle strength and power are developed by high intensity and low volume training.  \n gh intensity resistance training (HIRT) has led to increased protein synthesis, along with muscle hypertrophy measured at the whole body, whole muscle, and muscle fibre levels, in older adults. Typica \n t has been well documented that the increase in strength over the first few weeks of resistance training (i.e. acute) has a strong underlying neural component and further enhancement in strength with long-term (i.e. chronic) resistance training is due to muscle hypertrophy. For \n Low-intensity blood flow restricted (LI-BFR) resistance training has been shown to produce comparable increases in muscle hypertrophy to traditional high-intensity (HI) resistance training. Ho \n r adaptations caused by resistance training include increased cross-sectional area of the muscle (hypertrophy, hyperplasia, or both), selective hypertrophy of fast twitch fibers, decreased or maintained mitochondrial number and capillary density of muscle, and possible changes in energy sources. Changes in nerv \n Skeletal muscle hypertrophy following resistance training is accompanied by a fiber type-specific increase in satellite cell content in elderly men \n High-intensity resistance (HIR) training has been associated with muscle hypertrophy and decreased microvascular density that might produce a blood flow limitation.  \n The rate and amount of muscle hypertrophy associated with resistance training is influenced by a wide array of variables including the training program, plus training experience, gender, genetic predisposition, and nutritional status of the individual \n CONCLUSION: The results of this study suggest that pBFR can stimulate muscle hypertrophy to the same degree to that of high-intensity resistance trainin \n It is universally accepted that resistance training promotes increases in muscle strength and hypertrophy in younger and older populations \n Resistance training (RT) is a popular method of conditioning to enhance sport performance as well as an effective form of exercise to attenuate the age-mediated decline in muscle strength and mass \n Resistance training of healthy young men typically results in muscle hypertrophy and a shift in vastus lateralis composition away from type IIx fibers to an increase in IIa fiber content. \n Resistance training increases muscle size (i.e., causes hypertrophy) and muscle strength, particularly in untrained individuals. \n Hypertrophy is widely believed to be one of the mechanisms (i.e., a mediator) by which resistance training increases strength. \n Chronic resistance training induces increases in muscle fibre cross-sectional area (CSA), otherwise known as hypertrophy. \n The aim of the study was to determine whether it is possible to improve both maximum and rapid force production using resistance training that is typically used to induce muscle hypertrophy in previously untrained older men. \n Is an Energy Surplus Required to Maximize Skeletal Muscle Hypertrophy Associated With Resistance Training. \n We conclude that resistance training of prediabetic obese subjects is effective at changing muscle, resulting in fiber hypertrophy and increased type IIx fiber content, and these changes continue up to 16 wk of training.NEW & NOTEWORTHY Obese, insulin-resistant men responded to 16 wk of progressive resistance training with muscle hypertrophy and increased strength and a shift in muscle fiber composition toward fast-twitch, type IIx fibers. \n BACKGROUND: Effects of resistance training on muscle strength and hypertrophy are well established in adults and youn \n Increments in the cross-sectional area of muscle after resistance training can be primarily attributed to fibre hypertrophy. \n However, no data are reported in the literature to describe and compare the efficacy of the different hypertrophic resistance training strategies in hypoxia.Moreover, improvements in sprinting, jumping, or throwing performance have also been described at terrestrial altitude, encouraging research into the speed of explosive movements at altitude. \n We conclude that a program of resistance exercise can be safely carried out by elderly women, such a program significantly increases muscle strength, and such gains are due, at least in part, to muscle hypertrophy. \n Is resistance training usually associated with increasing muscle hypertrophy?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61f93cc7882a024a1000004c",
        "question": "337 (61\u00b74%) of 549 patients with nerinetide and 329 (59\u00b72%) of 556 with placebo achieved an mRS score of 0-2 at 90 days (adjusted risk ratio 1\u00b704, 95% CI 0\u00b796-1\u00b714; p=0\u00b735). Secondary outcomes were similar between groups.  \n INTERPRETATION: Nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. \n  patients receiving alteplase. Serious adverse events occurred equally between groups.INTERPRETATION: Nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo.FUNDING: Canadian Inst \n Is nerinetide effective for ischaemic stroke?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "61f938e7882a024a10000049",
        "question": " Median (IQR) overall survival was 14.9 (12.2-17.8) months in the standard group (N=158) and 14.3 (12.6-16.3) months in the experimental group (N = 145) (hazard ratio [HR] 1.02, 95% CI 0.66-1.58; P = 0.98). Median progression-free survival was 13.4 months in the standard group and 12.4 months in the experimental group (HR 1.33, 95% CI 0.72-1.78; P = 0.59). Grade 3 or higher adverse events occurred in 105 of 140 patients (75%) in the standard group and in 115 of 142 patients (81%) in the experimental group (P > 0.05).CONCLUSIONS: Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiation. \n CONCLUSIONS: The addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve survival. A multi-institutional, phase 3 study is ongoing \n CONCLUSIONS: The addition of algenpantucel-L to standard adjuvant therapy for resected pancreatic cancer may improve surviva \n CONCLUSIONS: Algenpantucel-L immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable PDAC receiving SOC neoadjuvant chemotherapy and chemoradiatio \n Is Algenpantucel-L effective for pancreatic cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "62515021e764a53204000018",
        "question": "the MICALs, which are flavoprotein monooxygenase/hydroxylase enzymes that associate with flavin adenine dinucleotide (FAD) and use the co-enzyme nicotinamide adenine dinucleotide phosphate (NADPH) in Redox reactions \n MICAL is an oxidoreductase \n We have recently identified a new family of multidomain oxidoreductase (redox) enzymes, the MICALs, \n the oxidoreductase MICAL \n Is Mical an oxidoreductase?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "61fa9a60c9dfcb9c09000007",
        "question": "CONCLUSIONS: Istiratumab failed to improve the efficacy of SOC chemotherapy in this patient setting.  \n In the high IGF-1 cohort, median PFS was 3.6 and 7.3 months in the experimental versus control arms, respectively [hazard ratio (HR)\u00a0= 1.88, P\u00a0= 0.027]. In the high IGF-1/HRG+ subgroup (n\u00a0= 44), median PFS was 4.1 and 7.3 months, respectively (HR\u00a0= 1.39, P\u00a0= 0.42). \n Should istiratumab be used for Pancreatic Cancer?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "no"
    },
    {
        "id": "605b9c2a94d57fd879000035",
        "question": "The main goal of our study is to assess the effect of transcranial magnetic stimulation, specifically theta burst stimulation (TBS), in a group of amblyopic volunteers measuring several visual parameters: visual acuity, suppressive imbalance, and stereoacuity \n This study was undertaken to determine if optometrists in Ghana screen, diagnose and manage paediatric ocular conditions (for example, strabismus, amblyopia), and further assessed if optometrists in Ghana have the requisite paediatric instrumentation in their practices. \n Many bilateral amblyopia patients have asymmetric visual acuity (VA). \n LTS: In patients with persistent amblyopia and in those with recovered amblyopia, the affected eyes were significantly more hyperopic than the fellow eyes. The \n e RNFLT was compared between the affected and fellow eyes in patients with persistent amblyopia and in those with recovered amblyopia, and between the amblyopic eyes of patients with persistent amblyopia and the previously amblyopic eyes of patients with recovered amblyopia.RE \n We compared the optic nerve head topography and retinal nerve fiber layer (RNFL) thickness of the strabismic and anisometropic amblyopic eyes with the normal fellow eyes and age-matched controls and concluded that, although amblyopia is a functional visual loss, RNFL thickness and optic nerve head topographic changes in strabismic and anisometropic amblyopic eyes may be affected by amblyopia. \n ODS: Four consecutive infants between 7 and 19 months of age with unilateral periocular vascular lesions that intermittently obstructed vision in the affected eye and no clinical evidence of amblyopia were evaluated. No  \n Histologic study of the LGNs from a patient with ophthalmologically confirmed anisometropic amblyopia shows a decrease of cell sizes in the parvocellular layers innervated by the amblyopic eye. \n S: Neutral density filters affect eyes with strabismic amblyopia differently than they do non-amblyopic eyes. A signifi \n Together with recent advances in our theoretical understanding of amblyopia and technological advances in amblyopia treatment, we anticipate improved visual outcomes for children affected by this very common eye condition. \n OBJECTIVE: Amblyopia or lazy eye is a common visual problem affecting children that cannot correct with lenses. \n Experimental amblyopia in animal models causes a reduction of cell sizes in lateral geniculate nucleus (LGN) laminae connected with the amblyopic eye. \n Amblyopia cannot be cured by treating the cause alone; the weaker eye must be made stronger in order to see normally. \n To correct amblyopia, a child must be made to use the weak eye. \n Similarly, decreased activation of the LGN as well as the visual cortex by the affected eye was demonstrated in the patient with anisometropic amblyopia. \n Amblyopia is defined as a loss of letter recognition visual acuity in the affected eye; however, studies in both nonhuman primates and man have shown that other important aspects of vision, including color, motion, and contour perception, are also abnormal. The \n Amblyopia is a developmental disorder that affects the spatial vision of one or both eyes in the absence of an obvious organic cause; it is associated with a history of abnormal visual experience during childhood \n Amblyopia is defined as the reduction of best-corrected visual acuity of one or both eyes caused by conditions that affect normal visual development \n Amblyopia is a reduced best-corrected visual acuity of one or both eyes that cannot be attributed to a structural abnormality; it is a functional reduction in the vision of an eye caused by disuse during a critical period of visual development \n Amblyopia is defined as reduced and uncorrectable vision in a structurally normal eye \n Amblyopia or \"lazy eye\" represents a disorder of the visual system characterized by poor vision in an eye that is otherwise physically normal.  \n Amblyopia is a common visual disorder that results in a spatial acuity deficit in the affected eye \n Amblyopia is a common deficit in spatial vision that could be based on either unreliable local estimates of image structure, irregularities in global image integration or a combination of errors at both these stages. \n Amblyopia is a disorder of visual acuity in one eye, thought to arise from suppression by the other eye during development of the visual cortex. \n Amblyopia is characterised by decrease in vision in one or both eyes as a result of processing defect in the visual pathways of the brain \n Amblyopia is defined as a loss of letter recognition visual acuity in the affected eye; however, studies in both nonhuman primates and man have shown that other important aspects of vision, including color, motion, and contour perception, are also abnormal \n Amblyopia, commonly known as \"lazy eye,\" is a frequent but preventable cause of decreased vision \n Here, we consider four explanations that may account for decreased fellow eye sensitivity: the fellow eye is adversely impacted by treatment for amblyopia; the maturation of the fellow eye is delayed by amblyopia; fellow eye sensitivity is impacted for visual functions that rely on binocular cortex; and fellow eye deficits reflect an adaptive mechanism that works to equalize the sensitivity of the two eyes \n Therefore, the aim of this review paper is to provide a comprehensive review of current knowledge about the effects of amblyopia on eye movements, upper limb reaching and grasping movements, as well as balance and gait \n Atropine occlusion in the treatment of strabismic amblyopia and its effect upon the non-amblyopic eye. \n Amblyopia is the most common cause of monocular visual impairment in children, with a prevalence of 2-3% \n Amblyopia is a neurodevelopmental disorder of the visual system, as a result of discordant visual experience during infancy or early childhood \n By its nature, however, amblyopia has an adverse effect on the development of a binocular visual system and the interactions between signals from two eyes. \n Unilateral Amblyopia Affects Two Eyes: Fellow Eye Deficits in Amblyopia. \n PURPOSE: Impairment of spatiotemporal visual processing is the hallmark of amblyopia, but its effects on eye movements during visuomotor tasks have rarely been \n Amblyopia is defined as a loss of letter recognition visual acuity in the affected eye; however, studies in both nonhuman primates and man have shown that other important aspects of vision, including color, motion, and contour perception, are also abnormal. \n Further research targeted at exploring fellow eye deficits in amblyopia will provide us with a broader understanding of normal visual development and how amblyopia impacts the developing visual system. \n While these fellow eye deficits have been noted, no overarching theory has been proposed to describe why and under what conditions the fellow eye is impacted by amblyopia. \n Here, we consider four explanations that may account for decreased fellow eye sensitivity: the fellow eye is adversely impacted by treatment for amblyopia; the maturation of the fellow eye is delayed by amblyopia; fellow eye sensitivity is impacted for visual functions that rely on binocular cortex; and fellow eye deficits reflect an adaptive mechanism that works to equalize the sensitivity of the two eyes. \n In anisometropes, the amblyopic eye influenced a relatively small proportion of cortical neurons; in strabismics, the influence of the two eyes was more nearly equal. \n studied. Here the authors investigate how visual deficits in anisometropic amblyopia affect saccadic eye movements.METHODS: Thirteen patients with anisometropic amblyopia and 13 control subj \n Unilateral amblyopia is a visual disorder that arises after selective disruption of visual input to one eye during critical periods of development. \n Amblyopia is a developmental disorder resulting in poor vision in one eye. \n In the clinic, amblyopia is understood as poor visual acuity in an eye that was deprived of pattern vision early in life. \n Ocular misalignment or unilateral blur often causes amblyopia, a disorder that has become a standard for understanding developmental plasticity. \n Amblyopia is a developmental disorder of pattern vision. \n  amblyopia are associated with poor PS. PS of amblyopic and fellow eyes is differentially  \n The contrast sensitivity function of both eyes of subjects with functional amblyopia has been measured. A clinically significant difference was found between the amblyopic and the normal eye. \n t appears that the functionally amblyopic eye takes more information from the peripheral parts of the stimulus than does the normal eye \n Previous studies focused on the differences between amblyopic patients and normal controls without evaluating amblyopic eyes after patching. To evaluate differences in the superficial vascular density of amblyopic eyes, normal eyes, and amblyopic eyes reaching normal BCVA after patch therapy, \n Does Amblyopia affect the eye?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    },
    {
        "id": "603bc2b61cb411341a00015b",
        "question": "However, we recently found that cerebrospinal fluid (CSF) concentration of the \"social\" neuropeptide arginine vasopressin (AVP) is significantly lower in pediatric ASD cases vs. controls. \n A large number of controlled trials demonstrated that exogenous oxytocin or arginine-vasopressin administration can mitigate social behavior impairment in ASD \n An accumulating body of evidence indicates a tight relationship between the endocrine system and abnormal social behavior. Two evolutionarily conserved hypothalamic peptides, oxytocin and arginine-vasopressin, because of their extensively documented function in supporting and regulating affiliative and socio-emotional responses, have attracted great interest for their critical implications for autism spectrum disorders (ASD \n Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD.  \n These preliminary findings suggest that AVP has potential for treating social impairments in children with ASD. \n The aim of this study was a systematic review of previous studies regarding the differences in OXT and vasopressin levels in ASD and neurotypical persons \n Differences in oxytocin and vasopressin levels in individuals suffering from the autism spectrum disorders vs general population - a systematic review. \n The contribution of oxytocin and vasopressin to mammalian social behavior: potential role in autism spectrum disorder. \n Although the mechanisms underlying its etiology and manifestations are poorly understood, several lines of evidence from rodent and human studies suggest involvement of the evolutionarily highly-conserved oxytocin (OXT) and arginine-vasopressin (AVP), as these neuropeptides modulate various aspects of mammalian social behavior. \n linical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD. Using \n Previous results suggest that OXT and arginine vasopressin (AVP) may play a role in the etiopathogenesis of ASD \n There has been intensified interest in the neuropeptides oxytocin (OT) and arginine vasopressin (AVP) in autism spectrum disorders (ASD) given their role in affiliative and social behavior in animals, positive results of treatment studies using OT, and findings that genetic polymorphisms in the AVP-OT pathway are present in individuals with ASD \n BACKGROUND: Arginine vasopressin (AVP) has been hypothesized to play a role in aetiology of autism based on a demonstrated involvement in the regulation of social \n Preclinical research suggests that arginine vasopressin (AVP), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for ASD. \n There has been intensified interest in the neuropeptides oxytocin (OT) and arginine vasopressin (AVP) in autism spectrum disorders (ASD) given their role in affiliative and social behavior in animals, positive results of treatment studies using OT, and findings that genetic polymorphisms in the AVP-OT pathway are present in individuals with ASD. \n We therefore hypothesized that AVP signaling deficits may contribute to social impairments in children with autism spectrum disorder (ASD). \n Given the emerging biological, animal model, and now genetic data, AVPR1a and genes in the AVP system remain strong candidates for involvement in autism susceptibility and deserve continued scrutiny. \n The behavioral effects of AVP are mediated through the AVP receptor 1a (AVPR1a), making the AVPR1a gene a reasonable candidate for autism susceptibility. \n Dysfunction of brain-derived arginine-vasopressin (AVP) systems may be involved in the etiology of autism spectrum disorder (ASD). \n These results strongly suggest that changes in structure and FC in brain regions containing AVP may be involved in the etiology of autism. \n Arginine Vasopressin Is a Blood-Based Biomarker of Social Functioning in Children with Autism. \n These findings also suggest that AVP biology may be a promising therapeutic target by which to improve social cognition in individuals with ASD. \n Genes Related to Oxytocin and Arginine-Vasopressin Pathways: Associations with Autism Spectrum Disorders. \n BACKGROUND: Dysregulation of the vasopressin (AVP) system has been implicated in the pathogenesis of autistic spectrum dis \n Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?",
        "choices": [
            "yes",
            "no"
        ],
        "answer": "yes"
    }
]